<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154086</url>
  </required_header>
  <id_info>
    <org_study_id>207440</org_study_id>
    <nct_id>NCT03154086</nct_id>
  </id_info>
  <brief_title>A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers</brief_title>
  <official_title>A Phase I, First Time in Human, Two Part, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Single and Repeat Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of
      escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers. This is a
      randomized, double-blind (sponsor unblinded), placebo controlled, dose escalation study that
      will have two parts; Part A and Part B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">March 5, 2018</completion_date>
  <primary_completion_date type="Actual">March 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1</measure>
    <time_frame>Up to 64 days in Cohort 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 2</measure>
    <time_frame>Up to 30 days in Cohort 2</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 3</measure>
    <time_frame>Up to 30 days in Cohort 3</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With SAEs and Non-SAEs</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 1</measure>
    <time_frame>Up to 64 days in Cohort 1</time_frame>
    <description>A complete physical examination will include, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 2</measure>
    <time_frame>Up to 30 days in Cohort 2</time_frame>
    <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 3</measure>
    <time_frame>Up to 30 days in Cohort 3</time_frame>
    <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Abnormal Findings After Physical Examination</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2</time_frame>
    <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT corrected (QTc) intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) findings for ECG parameters have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal ECG Findings in Cohort 2</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2</time_frame>
    <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Abnormal ECG Findings</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 7 (Pre-dose, 4 Hours Post-dose), Day 14 (Pre-dose, 4 Hours Post-dose), Follow-up (Day 25)</time_frame>
    <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug. The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in SBP and DBP in Cohort 2</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in SBP and DBP</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
    <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Pulse Rate in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Pulse Rate in Cohort 2</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
    <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Body Temperature in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Body Temperature in Cohort 2</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
    <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
    <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Different Stool Types Assessed Using Bristol Stool Form Scale (BSFS) in Cohort 1</measure>
    <time_frame>Up to 64 days in Cohort 1</time_frame>
    <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 2</measure>
    <time_frame>Up to 30 days in Cohort 2</time_frame>
    <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 3</measure>
    <time_frame>Up to 30 days in Cohort 3</time_frame>
    <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Average BSFS at Indicated Time Points</measure>
    <time_frame>Day -1, Days 1-3, Days 4-7, Days 1-7, Days 8-14</time_frame>
    <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythrocytes in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythrocytes in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Erythrocytes</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hemoglobin in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hemoglobin in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Hemoglobin</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythrocyte MCV in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Erythrocyte MCV</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythorocyte Mean Corpuscular Hemoglobin (MCH) in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Erythrocyte MCH in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Erythrocyte MCH</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hematocrit in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hematocrit in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Hematocrit</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST), Alkaline Phosphatase (Alk Phos) in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in ALT, AST and Alk Phos in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in ALT, AST and Alk Phos</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Albumin and Total Protein in Cohort 1 and 3</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin, and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Albumin and Total Protein in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Albumin, Total Protein</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 1 and Cohort 3</measure>
    <time_frame>Baseline (Day-1) and Day 3</time_frame>
    <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 2</measure>
    <time_frame>Baseline (Day -1) and Day 3</time_frame>
    <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Abnormal Findings for Urine Parameters</measure>
    <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
    <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Non-zero Concentration (AUC [0-t]) Following Single Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods. The PK Parameter population comprised of all randomized participants who received at least one dose of active treatment and who had GSK3352589 Pharmacokinetic parameter estimates from any portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Single Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Time to Reach Cmax (Tmax) Following Single Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Terminal Elimination Half-life (t1/2) Following Single Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including t1/2 following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cmax Following Single Dose Administration of GSK3352589-Food Effect</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC (0-t) Following Single Dose Administration of GSK3352589- Food Effect</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC (0-infinity) Following Single Dose Administration of GSK3352589- Food Effect</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: AUC (0-t) Following Repeat Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC [0-24]) Following Repeat Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-24) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-tau) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Cmax Following Repeat Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Tmax Following Repeat Dose Administration of GSK3352589</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
    <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cohort 2: Placebo Fasted/Placebo Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 3: GSK3352589 150 mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 3: Placebo/GSK3352589 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK3352589</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3352589</intervention_name>
    <description>It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.</description>
    <arm_group_label>Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg</arm_group_label>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo</arm_group_label>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg</arm_group_label>
    <arm_group_label>Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg</arm_group_label>
    <arm_group_label>Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed</arm_group_label>
    <arm_group_label>Part A:Cohort 3: GSK3352589 150 mg/Placebo</arm_group_label>
    <arm_group_label>Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg</arm_group_label>
    <arm_group_label>Part A:Cohort 3: Placebo/GSK3352589 400 mg</arm_group_label>
    <arm_group_label>Part B: GSK3352589</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>It will be available across all strengths to match active drug in the form of tablet for oral administration.</description>
    <arm_group_label>Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg</arm_group_label>
    <arm_group_label>Part A: Cohort 2: Placebo Fasted/Placebo Fed</arm_group_label>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo</arm_group_label>
    <arm_group_label>Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg</arm_group_label>
    <arm_group_label>Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg</arm_group_label>
    <arm_group_label>Part A:Cohort 3: GSK3352589 150 mg/Placebo</arm_group_label>
    <arm_group_label>Part A:Cohort 3: Placebo/GSK3352589 400 mg</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

          -  Healthy as determined by the investigator based on a medical evaluation including
             medical history, physical examination, laboratory tests and cardiac monitoring. -
             History of regular bowel habits

          -  Male or Female of non-childbearing potential.

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions.

        Exclusion Criteria:

          -  ALT and bilirubin &gt;1.5 x upper limit of normal (ULN) (isolated bilirubin &gt;1.5xULN is
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Previous Diagnosis of IBS

          -  Estimated Glomerular Filtration Rate &lt;60 millilter per minute per 1.73 square meter
             (mL/min/1.73m^2)

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)

          -  History of Gastroesophageal reflux disease (GERD), dyspepsia, Gastrointestinal (GI)
             bleeding, diverticulitis, diverticular stricture or other intestinal strictures, GI
             surgery that could affect motility

          -  Unwillingness or inability to follow the procedures outlined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <results_first_submitted>March 5, 2019</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2019</results_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REarranged during Transfection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a two-part study. Part A was a single dose escalating and Part B was a repeat dose escalating. Participants participated in either Part A or Part B of the study. This was a single center study, conducted at one site in Australia.</recruitment_details>
      <pre_assignment_details>A total number of 28 participants were enrolled in Part A and 40 participants were enrolled in Part B of the study. Participants in Part A, participated in one of the 3 Cohorts in Part A and Part B participants participated in one of the 5 Cohorts in Part B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg</title>
          <description>Participants received single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P2">
          <title>Part A:Cohort 1:GSK3352589 2mg/Placebo/GSK3352589 15mg/50mg</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P3">
          <title>Part A:Cohort 1: GSK3352589 2mg/ 5mg/Placebo/ GSK3352589 50mg</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P4">
          <title>Part A:Cohort 1:GSK3352589 2mg/5mg/15mg/Placebo</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P5">
          <title>Part A:Cohort 2:GSK3352589 25 mg Fasted/GSK3352589 25 mg Fed</title>
          <description>Participants received single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and in Period 2 (fed state). Participants returned for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P6">
          <title>Part A: Cohort 2: Placebo Fasted/Placebo Fed</title>
          <description>Participants received single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and in Period 2 (fed state). Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P7">
          <title>Part A:Cohort 3: GSK3352589 150 mg/Placebo</title>
          <description>Participants received single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P8">
          <title>Part A:Cohort 3: Placebo /GSK3352589 400 mg</title>
          <description>Participants received single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P9">
          <title>Part A:Cohort 3: GSK3352589 150 mg/GSK3352589 400 mg</title>
          <description>Participants received single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="P10">
          <title>Part B: Placebo BID</title>
          <description>Participants received repeat oral doses of placebo BID (twice a day) tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="P11">
          <title>Part B: GSK3352589 5 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 5 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="P12">
          <title>Part B: GSK3352589 15 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 15 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="P13">
          <title>Part B: GSK3352589 50 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 50 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="P14">
          <title>Part B: GSK3352589 100 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="P15">
          <title>Part B: GSK3352589 200 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A: Cohort1 Period1 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort1 Washout1 (Up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Cohort1 Period2 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2">One replacement participant (par) was enrolled and dosed</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>PartA: Cohort1 Washout2 (Up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Cohort1 Period3 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2">One replacement par was enrolled and dosed</participants>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort1 Washout3 (Up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Cohort1 Period4 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">1 par was not dosed on day of dosing due to elevated lab; hence 1 replacement was enrolled and dosed</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Cohort2 Period1 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort2 Washout1 (Up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort2 Period2 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort3 Period1 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort3 Washout1 (Up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Cohort3 Period2 (Up to 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="5">1 par was unwell on Day-1 of Period 2 and discontinued; hence,1 replacement was enrolled and dosed</participants>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Up to 25 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg</title>
          <description>Participants received single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B2">
          <title>Part A:Cohort 1:GSK3352589 2mg/Placebo/GSK3352589 15mg/50mg</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B3">
          <title>Part A:Cohort 1: GSK3352589 2mg/ 5mg/Placebo/ GSK3352589 50mg</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B4">
          <title>Part A:Cohort 1:GSK3352589 2mg/5mg/15mg/Placebo</title>
          <description>Participants received single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B5">
          <title>Part A:Cohort 2:GSK3352589 25 mg Fasted/GSK3352589 25 mg Fed</title>
          <description>Participants received single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and in Period 2 (fed state). Participants returned for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B6">
          <title>Part A: Cohort 2: Placebo Fasted/Placebo Fed</title>
          <description>Participants received single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and in Period 2 (fed state). Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B7">
          <title>Part A:Cohort 3: GSK3352589 150 mg/Placebo</title>
          <description>Participants received single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B8">
          <title>Part A:Cohort 3: Placebo /GSK3352589 400 mg</title>
          <description>Participants received single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B9">
          <title>Part A:Cohort 3: GSK3352589 150 mg/GSK3352589 400 mg</title>
          <description>Participants received single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Participants returned for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.</description>
        </group>
        <group group_id="B10">
          <title>Part B: Placebo BID</title>
          <description>Participants received repeat oral doses of placebo BID (twice a day) tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B11">
          <title>Part B: GSK3352589 5 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 5 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B12">
          <title>Part B: GSK3352589 15 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 15 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B13">
          <title>Part B: GSK3352589 50 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 50 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B14">
          <title>Part B: GSK3352589 100 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B15">
          <title>Part B: GSK3352589 200 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="6"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="14.00"/>
                    <measurement group_id="B2" value="26.7" spread="4.73"/>
                    <measurement group_id="B3" value="33.5" spread="9.19"/>
                    <measurement group_id="B4" value="41.0" spread="5.20"/>
                    <measurement group_id="B5" value="29.7" spread="8.57"/>
                    <measurement group_id="B6" value="34.5" spread="3.54"/>
                    <measurement group_id="B7" value="40.5" spread="7.78"/>
                    <measurement group_id="B8" value="44.5" spread="0.71"/>
                    <measurement group_id="B9" value="28.8" spread="7.43"/>
                    <measurement group_id="B10" value="25.5" spread="5.40"/>
                    <measurement group_id="B11" value="30.8" spread="8.11"/>
                    <measurement group_id="B12" value="33.3" spread="8.45"/>
                    <measurement group_id="B13" value="23.3" spread="2.88"/>
                    <measurement group_id="B14" value="23.7" spread="4.59"/>
                    <measurement group_id="B15" value="32.2" spread="11.20"/>
                    <measurement group_id="B16" value="30.5" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Native-Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
        <time_frame>Up to 64 days in Cohort 1</time_frame>
        <population>Safety Population comprised of all randomized participants who received at least one dose of study medication and was based on the actual treatment received, if this differed from that to which the participant was randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 orally in one of the Periods of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
          <population>Safety Population comprised of all randomized participants who received at least one dose of study medication and was based on the actual treatment received, if this differed from that to which the participant was randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 2</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
        <time_frame>Up to 30 days in Cohort 2</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 2</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 3</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
        <time_frame>Up to 30 days in Cohort 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With SAEs and Non-SAEs in Cohort 3</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With SAEs and Non-SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With SAEs and Non-SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 1</title>
        <description>A complete physical examination will include, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
        <time_frame>Up to 64 days in Cohort 1</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 orally in one of the Periods of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 1</title>
          <description>A complete physical examination will include, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 2</title>
        <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
        <time_frame>Up to 30 days in Cohort 2</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 2</title>
          <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 3</title>
        <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
        <time_frame>Up to 30 days in Cohort 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 3</title>
          <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Abnormal Findings After Physical Examination</title>
        <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Abnormal Findings After Physical Examination</title>
          <description>A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Brief symptom directed physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Number of participants with clinically significant abnormal physical examination findings have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in Cohort 1 and Cohort 3</title>
        <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT corrected (QTc) intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) findings for ECG parameters have been presented.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in Cohort 1 and Cohort 3</title>
          <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT corrected (QTc) intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) findings for ECG parameters have been presented.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1; Pre-dose); Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Day 1; Pre-dose); Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 1 Hour Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 1 Hour Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal ECG Findings in Cohort 2</title>
        <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal ECG Findings in Cohort 2</title>
          <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1; Pre-dose); Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline; (Day 1;pre dose); Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 1 Hour Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 1 Hour Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Abnormal ECG Findings</title>
        <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug. The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 7 (Pre-dose, 4 Hours Post-dose), Day 14 (Pre-dose, 4 Hours Post-dose), Follow-up (Day 25)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Abnormal ECG Findings</title>
          <description>Triplicate 12-lead ECGs were obtained at indicated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline is defined as the last available, non-missing mean value of triplicate assessment prior to the first administration of study drug. The number of participants with abnormal CS and NCS findings for ECG parameters have been presented.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1; Pre-dose); Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Day 1; Pre-dose); Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7; Pre-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7; Pre-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7; 4 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7; 4 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; Pre-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; Pre-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 4 Hours Post-dose; Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 4 Hours Post-dose; Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Cohort 1 and Cohort 3</title>
        <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Cohort 1 and Cohort 3</title>
          <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="9.61"/>
                    <measurement group_id="O2" value="-1.75" spread="4.71"/>
                    <measurement group_id="O3" value="-2.08" spread="11.72"/>
                    <measurement group_id="O4" value="3.00" spread="9.72"/>
                    <measurement group_id="O5" value="-2.70" spread="12.26"/>
                    <measurement group_id="O6" value="1.58" spread="5.55"/>
                    <measurement group_id="O7" value="-0.10" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="11.32"/>
                    <measurement group_id="O2" value="-5.83" spread="5.86"/>
                    <measurement group_id="O3" value="-1.33" spread="13.56"/>
                    <measurement group_id="O4" value="3.75" spread="11.04"/>
                    <measurement group_id="O5" value="-3.60" spread="14.72"/>
                    <measurement group_id="O6" value="-1.75" spread="3.27"/>
                    <measurement group_id="O7" value="1.40" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="8.65"/>
                    <measurement group_id="O2" value="-3.83" spread="10.11"/>
                    <measurement group_id="O3" value="1.08" spread="11.33"/>
                    <measurement group_id="O4" value="3.00" spread="10.39"/>
                    <measurement group_id="O5" value="3.10" spread="9.15"/>
                    <measurement group_id="O6" value="1.33" spread="4.07"/>
                    <measurement group_id="O7" value="3.90" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="10.00"/>
                    <measurement group_id="O2" value="-4.50" spread="5.74"/>
                    <measurement group_id="O3" value="-1.42" spread="9.77"/>
                    <measurement group_id="O4" value="-2.17" spread="10.87"/>
                    <measurement group_id="O5" value="-3.40" spread="7.54"/>
                    <measurement group_id="O6" value="1.50" spread="2.53"/>
                    <measurement group_id="O7" value="-5.00" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.63" spread="11.05"/>
                    <measurement group_id="O2" value="-8.67" spread="5.12"/>
                    <measurement group_id="O3" value="-0.42" spread="16.59"/>
                    <measurement group_id="O4" value="1.92" spread="7.05"/>
                    <measurement group_id="O5" value="-3.30" spread="10.12"/>
                    <measurement group_id="O6" value="0.67" spread="4.17"/>
                    <measurement group_id="O7" value="0.60" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="5.62"/>
                    <measurement group_id="O2" value="-0.67" spread="3.89"/>
                    <measurement group_id="O3" value="1.75" spread="4.71"/>
                    <measurement group_id="O4" value="1.08" spread="7.34"/>
                    <measurement group_id="O5" value="1.00" spread="10.31"/>
                    <measurement group_id="O6" value="0.33" spread="4.01"/>
                    <measurement group_id="O7" value="4.20" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="5.87"/>
                    <measurement group_id="O2" value="-0.42" spread="5.33"/>
                    <measurement group_id="O3" value="-1.83" spread="5.39"/>
                    <measurement group_id="O4" value="2.25" spread="9.95"/>
                    <measurement group_id="O5" value="-2.10" spread="6.07"/>
                    <measurement group_id="O6" value="1.17" spread="4.77"/>
                    <measurement group_id="O7" value="6.50" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="5.67"/>
                    <measurement group_id="O2" value="-4.42" spread="6.58"/>
                    <measurement group_id="O3" value="-3.08" spread="5.29"/>
                    <measurement group_id="O4" value="-5.75" spread="5.33"/>
                    <measurement group_id="O5" value="-4.10" spread="8.13"/>
                    <measurement group_id="O6" value="-1.08" spread="5.30"/>
                    <measurement group_id="O7" value="0.40" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="4.71"/>
                    <measurement group_id="O2" value="-2.58" spread="7.91"/>
                    <measurement group_id="O3" value="-2.25" spread="4.10"/>
                    <measurement group_id="O4" value="-1.17" spread="4.01"/>
                    <measurement group_id="O5" value="-5.40" spread="3.44"/>
                    <measurement group_id="O6" value="-0.17" spread="5.34"/>
                    <measurement group_id="O7" value="3.60" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="6.30"/>
                    <measurement group_id="O2" value="-2.67" spread="7.72"/>
                    <measurement group_id="O3" value="2.67" spread="5.65"/>
                    <measurement group_id="O4" value="-1.50" spread="6.43"/>
                    <measurement group_id="O5" value="-2.20" spread="4.27"/>
                    <measurement group_id="O6" value="0.75" spread="4.97"/>
                    <measurement group_id="O7" value="3.80" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in SBP and DBP in Cohort 2</title>
        <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in SBP and DBP in Cohort 2</title>
          <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="3.89"/>
                    <measurement group_id="O2" value="6.00" spread="8.49"/>
                    <measurement group_id="O3" value="3.75" spread="9.68"/>
                    <measurement group_id="O4" value="-6.58" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.06"/>
                    <measurement group_id="O2" value="-6.50" spread="9.19"/>
                    <measurement group_id="O3" value="-5.17" spread="11.44"/>
                    <measurement group_id="O4" value="-6.25" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="9.55"/>
                    <measurement group_id="O2" value="10.75" spread="15.91"/>
                    <measurement group_id="O3" value="1.50" spread="10.84"/>
                    <measurement group_id="O4" value="1.50" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.75" spread="5.30"/>
                    <measurement group_id="O2" value="-3.75" spread="4.60"/>
                    <measurement group_id="O3" value="-7.58" spread="5.18"/>
                    <measurement group_id="O4" value="-5.00" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.35"/>
                    <measurement group_id="O2" value="6.75" spread="10.96"/>
                    <measurement group_id="O3" value="-4.50" spread="8.06"/>
                    <measurement group_id="O4" value="1.00" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="3.89"/>
                    <measurement group_id="O2" value="-5.75" spread="2.47"/>
                    <measurement group_id="O3" value="1.67" spread="6.23"/>
                    <measurement group_id="O4" value="-4.25" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="3.18"/>
                    <measurement group_id="O2" value="-5.00" spread="3.54"/>
                    <measurement group_id="O3" value="-1.67" spread="7.10"/>
                    <measurement group_id="O4" value="-4.75" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.25" spread="2.47"/>
                    <measurement group_id="O2" value="-3.00" spread="2.83"/>
                    <measurement group_id="O3" value="-2.67" spread="6.92"/>
                    <measurement group_id="O4" value="-6.00" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="2.12"/>
                    <measurement group_id="O2" value="-5.25" spread="6.72"/>
                    <measurement group_id="O3" value="-1.92" spread="4.41"/>
                    <measurement group_id="O4" value="-2.75" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="8.49"/>
                    <measurement group_id="O2" value="0.75" spread="7.42"/>
                    <measurement group_id="O3" value="3.58" spread="6.94"/>
                    <measurement group_id="O4" value="2.08" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in SBP and DBP</title>
        <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in SBP and DBP</title>
          <description>Blood pressure of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; Day 1; 4 Hours Post dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="7.00"/>
                    <measurement group_id="O2" value="-1.83" spread="6.59"/>
                    <measurement group_id="O3" value="-2.33" spread="6.01"/>
                    <measurement group_id="O4" value="1.17" spread="10.69"/>
                    <measurement group_id="O5" value="-2.33" spread="11.79"/>
                    <measurement group_id="O6" value="-8.08" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 2; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.35" spread="5.61"/>
                    <measurement group_id="O2" value="-6.25" spread="5.37"/>
                    <measurement group_id="O3" value="-5.75" spread="7.37"/>
                    <measurement group_id="O4" value="-2.33" spread="13.01"/>
                    <measurement group_id="O5" value="-4.08" spread="12.69"/>
                    <measurement group_id="O6" value="-9.42" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 3; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.90" spread="6.50"/>
                    <measurement group_id="O2" value="-5.25" spread="13.97"/>
                    <measurement group_id="O3" value="-1.42" spread="6.42"/>
                    <measurement group_id="O4" value="-9.83" spread="18.11"/>
                    <measurement group_id="O5" value="-6.83" spread="11.57"/>
                    <measurement group_id="O6" value="-5.58" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 4; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.75" spread="6.91"/>
                    <measurement group_id="O2" value="-5.83" spread="9.23"/>
                    <measurement group_id="O3" value="0.83" spread="8.88"/>
                    <measurement group_id="O4" value="-0.08" spread="15.46"/>
                    <measurement group_id="O5" value="-9.08" spread="11.13"/>
                    <measurement group_id="O6" value="-9.42" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 5; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.55" spread="8.39"/>
                    <measurement group_id="O2" value="-7.00" spread="5.85"/>
                    <measurement group_id="O3" value="-1.08" spread="5.39"/>
                    <measurement group_id="O4" value="-9.33" spread="18.90"/>
                    <measurement group_id="O5" value="-3.92" spread="14.39"/>
                    <measurement group_id="O6" value="-11.17" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 6; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.65" spread="6.93"/>
                    <measurement group_id="O2" value="-5.33" spread="8.52"/>
                    <measurement group_id="O3" value="-5.42" spread="4.25"/>
                    <measurement group_id="O4" value="-6.50" spread="13.10"/>
                    <measurement group_id="O5" value="-4.08" spread="16.53"/>
                    <measurement group_id="O6" value="-10.33" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 7, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="8.36"/>
                    <measurement group_id="O2" value="-9.75" spread="6.57"/>
                    <measurement group_id="O3" value="-7.83" spread="5.85"/>
                    <measurement group_id="O4" value="-7.83" spread="14.75"/>
                    <measurement group_id="O5" value="-3.50" spread="10.48"/>
                    <measurement group_id="O6" value="-3.92" spread="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 7, 4 Hours Post-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" spread="5.61"/>
                    <measurement group_id="O2" value="-6.92" spread="6.50"/>
                    <measurement group_id="O3" value="-6.67" spread="7.93"/>
                    <measurement group_id="O4" value="-6.92" spread="10.58"/>
                    <measurement group_id="O5" value="-5.92" spread="15.81"/>
                    <measurement group_id="O6" value="-7.50" spread="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 8; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.95" spread="5.71"/>
                    <measurement group_id="O2" value="-6.00" spread="9.87"/>
                    <measurement group_id="O3" value="-7.67" spread="14.50"/>
                    <measurement group_id="O4" value="-4.50" spread="10.31"/>
                    <measurement group_id="O5" value="-8.00" spread="9.98"/>
                    <measurement group_id="O6" value="-4.75" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 9; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.90" spread="9.74"/>
                    <measurement group_id="O2" value="0.67" spread="11.89"/>
                    <measurement group_id="O3" value="-5.83" spread="5.19"/>
                    <measurement group_id="O4" value="-11.08" spread="15.23"/>
                    <measurement group_id="O5" value="-8.33" spread="11.99"/>
                    <measurement group_id="O6" value="-9.00" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 10; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.15" spread="7.34"/>
                    <measurement group_id="O2" value="-5.67" spread="7.15"/>
                    <measurement group_id="O3" value="-1.67" spread="6.25"/>
                    <measurement group_id="O4" value="-7.67" spread="15.08"/>
                    <measurement group_id="O5" value="-9.50" spread="13.57"/>
                    <measurement group_id="O6" value="-15.67" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 11; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.60" spread="8.03"/>
                    <measurement group_id="O2" value="-5.00" spread="9.42"/>
                    <measurement group_id="O3" value="-3.83" spread="14.31"/>
                    <measurement group_id="O4" value="-7.25" spread="16.23"/>
                    <measurement group_id="O5" value="-8.42" spread="10.95"/>
                    <measurement group_id="O6" value="-9.50" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 12; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.50" spread="9.06"/>
                    <measurement group_id="O2" value="-5.58" spread="10.74"/>
                    <measurement group_id="O3" value="-0.08" spread="10.03"/>
                    <measurement group_id="O4" value="-4.00" spread="18.10"/>
                    <measurement group_id="O5" value="-9.33" spread="13.52"/>
                    <measurement group_id="O6" value="-4.25" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 13; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.15" spread="7.63"/>
                    <measurement group_id="O2" value="-5.33" spread="10.30"/>
                    <measurement group_id="O3" value="-1.58" spread="6.96"/>
                    <measurement group_id="O4" value="-6.67" spread="17.26"/>
                    <measurement group_id="O5" value="-8.08" spread="16.69"/>
                    <measurement group_id="O6" value="-6.58" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 14, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.90" spread="9.73"/>
                    <measurement group_id="O2" value="-5.42" spread="7.64"/>
                    <measurement group_id="O3" value="-0.25" spread="3.76"/>
                    <measurement group_id="O4" value="-1.83" spread="15.28"/>
                    <measurement group_id="O5" value="0.83" spread="10.93"/>
                    <measurement group_id="O6" value="-9.50" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 14, 4 Hours Post-dose; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="9.48"/>
                    <measurement group_id="O2" value="-8.50" spread="8.12"/>
                    <measurement group_id="O3" value="0.50" spread="7.13"/>
                    <measurement group_id="O4" value="-13.00" spread="13.90"/>
                    <measurement group_id="O5" value="-0.25" spread="13.15"/>
                    <measurement group_id="O6" value="-5.67" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="10.20"/>
                    <measurement group_id="O2" value="-1.00" spread="6.78"/>
                    <measurement group_id="O3" value="8.08" spread="8.11"/>
                    <measurement group_id="O4" value="-5.92" spread="14.17"/>
                    <measurement group_id="O5" value="2.67" spread="13.53"/>
                    <measurement group_id="O6" value="-5.42" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.85" spread="9.32"/>
                    <measurement group_id="O2" value="-4.42" spread="11.63"/>
                    <measurement group_id="O3" value="-3.67" spread="7.74"/>
                    <measurement group_id="O4" value="0.08" spread="11.00"/>
                    <measurement group_id="O5" value="-1.08" spread="12.64"/>
                    <measurement group_id="O6" value="-2.83" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 1; 4 Hours Post dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.90" spread="5.78"/>
                    <measurement group_id="O2" value="-2.17" spread="5.27"/>
                    <measurement group_id="O3" value="-1.42" spread="6.92"/>
                    <measurement group_id="O4" value="-2.08" spread="5.56"/>
                    <measurement group_id="O5" value="-5.00" spread="7.06"/>
                    <measurement group_id="O6" value="-3.33" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 2; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="4.83"/>
                    <measurement group_id="O2" value="1.50" spread="9.84"/>
                    <measurement group_id="O3" value="-1.67" spread="5.60"/>
                    <measurement group_id="O4" value="-3.67" spread="8.22"/>
                    <measurement group_id="O5" value="-3.17" spread="7.47"/>
                    <measurement group_id="O6" value="-2.25" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 3; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.30" spread="5.30"/>
                    <measurement group_id="O2" value="0.08" spread="6.64"/>
                    <measurement group_id="O3" value="-2.75" spread="4.91"/>
                    <measurement group_id="O4" value="-3.50" spread="6.19"/>
                    <measurement group_id="O5" value="-5.00" spread="6.54"/>
                    <measurement group_id="O6" value="-2.17" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 4; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.05" spread="6.89"/>
                    <measurement group_id="O2" value="-0.58" spread="10.28"/>
                    <measurement group_id="O3" value="-1.33" spread="4.54"/>
                    <measurement group_id="O4" value="-3.00" spread="5.93"/>
                    <measurement group_id="O5" value="-3.33" spread="2.82"/>
                    <measurement group_id="O6" value="-3.67" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 5; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="9.26"/>
                    <measurement group_id="O2" value="-1.67" spread="5.67"/>
                    <measurement group_id="O3" value="-4.17" spread="3.92"/>
                    <measurement group_id="O4" value="-8.25" spread="7.90"/>
                    <measurement group_id="O5" value="-3.58" spread="6.44"/>
                    <measurement group_id="O6" value="-3.33" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 6; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.20" spread="7.37"/>
                    <measurement group_id="O2" value="-1.67" spread="4.83"/>
                    <measurement group_id="O3" value="-3.25" spread="6.02"/>
                    <measurement group_id="O4" value="-7.25" spread="5.82"/>
                    <measurement group_id="O5" value="-3.00" spread="7.54"/>
                    <measurement group_id="O6" value="-6.67" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 7, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.20" spread="7.52"/>
                    <measurement group_id="O2" value="-4.17" spread="4.67"/>
                    <measurement group_id="O3" value="-6.75" spread="7.76"/>
                    <measurement group_id="O4" value="-5.17" spread="5.83"/>
                    <measurement group_id="O5" value="4.58" spread="3.99"/>
                    <measurement group_id="O6" value="0.33" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 7, 4 Hours Post-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.65" spread="7.04"/>
                    <measurement group_id="O2" value="-3.75" spread="4.12"/>
                    <measurement group_id="O3" value="-5.92" spread="4.62"/>
                    <measurement group_id="O4" value="-6.83" spread="6.12"/>
                    <measurement group_id="O5" value="-2.75" spread="7.06"/>
                    <measurement group_id="O6" value="-3.67" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 8; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.20" spread="6.86"/>
                    <measurement group_id="O2" value="-1.75" spread="9.42"/>
                    <measurement group_id="O3" value="-5.50" spread="9.49"/>
                    <measurement group_id="O4" value="-2.75" spread="8.93"/>
                    <measurement group_id="O5" value="-1.25" spread="4.47"/>
                    <measurement group_id="O6" value="-4.42" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 9; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" spread="8.36"/>
                    <measurement group_id="O2" value="-1.08" spread="8.67"/>
                    <measurement group_id="O3" value="-3.08" spread="4.19"/>
                    <measurement group_id="O4" value="-8.00" spread="9.17"/>
                    <measurement group_id="O5" value="-6.75" spread="7.13"/>
                    <measurement group_id="O6" value="-4.42" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 10; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.35" spread="8.93"/>
                    <measurement group_id="O2" value="1.50" spread="4.71"/>
                    <measurement group_id="O3" value="-3.00" spread="7.22"/>
                    <measurement group_id="O4" value="-5.25" spread="6.26"/>
                    <measurement group_id="O5" value="-2.42" spread="8.75"/>
                    <measurement group_id="O6" value="-6.50" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 11; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.80" spread="10.14"/>
                    <measurement group_id="O2" value="-1.25" spread="8.60"/>
                    <measurement group_id="O3" value="-4.58" spread="7.37"/>
                    <measurement group_id="O4" value="-6.25" spread="7.01"/>
                    <measurement group_id="O5" value="-5.08" spread="4.73"/>
                    <measurement group_id="O6" value="-3.92" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 12; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.95" spread="5.44"/>
                    <measurement group_id="O2" value="-2.67" spread="8.65"/>
                    <measurement group_id="O3" value="-1.42" spread="4.44"/>
                    <measurement group_id="O4" value="-5.42" spread="7.81"/>
                    <measurement group_id="O5" value="-2.00" spread="3.79"/>
                    <measurement group_id="O6" value="-0.50" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 13; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.55" spread="8.26"/>
                    <measurement group_id="O2" value="-1.42" spread="10.70"/>
                    <measurement group_id="O3" value="-2.50" spread="5.13"/>
                    <measurement group_id="O4" value="-2.92" spread="8.23"/>
                    <measurement group_id="O5" value="-1.08" spread="5.70"/>
                    <measurement group_id="O6" value="-2.67" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 14, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.10" spread="7.05"/>
                    <measurement group_id="O2" value="-4.25" spread="6.19"/>
                    <measurement group_id="O3" value="0.17" spread="5.69"/>
                    <measurement group_id="O4" value="-3.58" spread="5.10"/>
                    <measurement group_id="O5" value="2.67" spread="3.66"/>
                    <measurement group_id="O6" value="-0.83" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 14, 4 Hours Post-dose; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.65" spread="7.12"/>
                    <measurement group_id="O2" value="-6.80" spread="8.25"/>
                    <measurement group_id="O3" value="-3.58" spread="4.87"/>
                    <measurement group_id="O4" value="-8.83" spread="7.45"/>
                    <measurement group_id="O5" value="5.00" spread="5.68"/>
                    <measurement group_id="O6" value="0.33" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.75" spread="10.22"/>
                    <measurement group_id="O2" value="1.30" spread="7.13"/>
                    <measurement group_id="O3" value="2.00" spread="7.47"/>
                    <measurement group_id="O4" value="-5.67" spread="6.47"/>
                    <measurement group_id="O5" value="2.00" spread="8.40"/>
                    <measurement group_id="O6" value="-4.08" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.85" spread="8.87"/>
                    <measurement group_id="O2" value="-3.92" spread="7.56"/>
                    <measurement group_id="O3" value="-1.75" spread="5.10"/>
                    <measurement group_id="O4" value="-1.75" spread="8.62"/>
                    <measurement group_id="O5" value="1.00" spread="5.06"/>
                    <measurement group_id="O6" value="-1.17" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Pulse Rate in Cohort 1 and Cohort 3</title>
        <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Pulse Rate in Cohort 1 and Cohort 3</title>
          <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.79" spread="6.30"/>
                    <measurement group_id="O2" value="-3.25" spread="4.39"/>
                    <measurement group_id="O3" value="-3.00" spread="6.66"/>
                    <measurement group_id="O4" value="-3.25" spread="6.93"/>
                    <measurement group_id="O5" value="-4.00" spread="7.44"/>
                    <measurement group_id="O6" value="-2.75" spread="5.69"/>
                    <measurement group_id="O7" value="-3.20" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.42" spread="5.91"/>
                    <measurement group_id="O2" value="-4.92" spread="5.98"/>
                    <measurement group_id="O3" value="-4.67" spread="6.59"/>
                    <measurement group_id="O4" value="-0.75" spread="7.96"/>
                    <measurement group_id="O5" value="-6.90" spread="5.03"/>
                    <measurement group_id="O6" value="-3.67" spread="4.70"/>
                    <measurement group_id="O7" value="-3.40" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="6.34"/>
                    <measurement group_id="O2" value="0.75" spread="3.40"/>
                    <measurement group_id="O3" value="5.83" spread="6.04"/>
                    <measurement group_id="O4" value="6.00" spread="3.10"/>
                    <measurement group_id="O5" value="0.40" spread="8.93"/>
                    <measurement group_id="O6" value="2.33" spread="3.88"/>
                    <measurement group_id="O7" value="2.40" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="9.11"/>
                    <measurement group_id="O2" value="-3.33" spread="7.77"/>
                    <measurement group_id="O3" value="-2.42" spread="6.90"/>
                    <measurement group_id="O4" value="2.08" spread="4.57"/>
                    <measurement group_id="O5" value="-3.60" spread="7.21"/>
                    <measurement group_id="O6" value="-2.83" spread="2.14"/>
                    <measurement group_id="O7" value="-1.60" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="7.17"/>
                    <measurement group_id="O2" value="-0.08" spread="10.84"/>
                    <measurement group_id="O3" value="-1.75" spread="9.49"/>
                    <measurement group_id="O4" value="0.50" spread="7.06"/>
                    <measurement group_id="O5" value="-2.50" spread="10.62"/>
                    <measurement group_id="O6" value="-2.08" spread="5.44"/>
                    <measurement group_id="O7" value="0.50" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Pulse Rate in Cohort 2</title>
        <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Pulse Rate in Cohort 2</title>
          <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.41"/>
                    <measurement group_id="O2" value="7.50" spread="0.71"/>
                    <measurement group_id="O3" value="0.42" spread="4.98"/>
                    <measurement group_id="O4" value="9.08" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="2.47"/>
                    <measurement group_id="O2" value="-1.00" spread="2.12"/>
                    <measurement group_id="O3" value="-1.33" spread="3.87"/>
                    <measurement group_id="O4" value="2.75" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="2.12"/>
                    <measurement group_id="O2" value="9.25" spread="0.35"/>
                    <measurement group_id="O3" value="9.33" spread="3.42"/>
                    <measurement group_id="O4" value="7.92" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="3.89"/>
                    <measurement group_id="O2" value="3.00" spread="4.24"/>
                    <measurement group_id="O3" value="4.33" spread="4.74"/>
                    <measurement group_id="O4" value="3.17" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="4.95"/>
                    <measurement group_id="O2" value="4.75" spread="3.18"/>
                    <measurement group_id="O3" value="6.92" spread="7.12"/>
                    <measurement group_id="O4" value="7.58" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Pulse Rate</title>
        <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Pulse Rate</title>
          <description>Pulse rate of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 4 Hours Post dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="4.75"/>
                    <measurement group_id="O2" value="-0.42" spread="8.65"/>
                    <measurement group_id="O3" value="-2.25" spread="4.16"/>
                    <measurement group_id="O4" value="-3.58" spread="4.90"/>
                    <measurement group_id="O5" value="-1.17" spread="7.13"/>
                    <measurement group_id="O6" value="-3.42" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="7.07"/>
                    <measurement group_id="O2" value="2.50" spread="10.80"/>
                    <measurement group_id="O3" value="-0.25" spread="5.52"/>
                    <measurement group_id="O4" value="0.50" spread="8.63"/>
                    <measurement group_id="O5" value="-2.67" spread="7.28"/>
                    <measurement group_id="O6" value="0.08" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="4.53"/>
                    <measurement group_id="O2" value="3.33" spread="7.05"/>
                    <measurement group_id="O3" value="0.58" spread="5.62"/>
                    <measurement group_id="O4" value="1.08" spread="8.34"/>
                    <measurement group_id="O5" value="-6.92" spread="8.45"/>
                    <measurement group_id="O6" value="-2.25" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="8.47"/>
                    <measurement group_id="O2" value="2.42" spread="10.53"/>
                    <measurement group_id="O3" value="-1.67" spread="3.80"/>
                    <measurement group_id="O4" value="1.33" spread="9.10"/>
                    <measurement group_id="O5" value="2.58" spread="9.16"/>
                    <measurement group_id="O6" value="-0.17" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="6.03"/>
                    <measurement group_id="O2" value="-1.17" spread="9.03"/>
                    <measurement group_id="O3" value="2.75" spread="6.83"/>
                    <measurement group_id="O4" value="1.92" spread="9.09"/>
                    <measurement group_id="O5" value="-0.25" spread="9.96"/>
                    <measurement group_id="O6" value="3.92" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="5.33"/>
                    <measurement group_id="O2" value="5.42" spread="11.74"/>
                    <measurement group_id="O3" value="-0.33" spread="8.94"/>
                    <measurement group_id="O4" value="-1.33" spread="8.24"/>
                    <measurement group_id="O5" value="0.08" spread="9.04"/>
                    <measurement group_id="O6" value="-2.67" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="5.23"/>
                    <measurement group_id="O2" value="0.25" spread="8.30"/>
                    <measurement group_id="O3" value="-0.25" spread="10.24"/>
                    <measurement group_id="O4" value="-0.75" spread="5.66"/>
                    <measurement group_id="O5" value="0.50" spread="9.44"/>
                    <measurement group_id="O6" value="-0.25" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 Hours Post-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="4.82"/>
                    <measurement group_id="O2" value="3.75" spread="10.14"/>
                    <measurement group_id="O3" value="-5.08" spread="5.38"/>
                    <measurement group_id="O4" value="-0.58" spread="5.52"/>
                    <measurement group_id="O5" value="-1.25" spread="7.29"/>
                    <measurement group_id="O6" value="1.17" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="7.37"/>
                    <measurement group_id="O2" value="1.42" spread="9.06"/>
                    <measurement group_id="O3" value="1.42" spread="6.15"/>
                    <measurement group_id="O4" value="2.08" spread="7.28"/>
                    <measurement group_id="O5" value="-0.17" spread="10.75"/>
                    <measurement group_id="O6" value="5.83" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="8.59"/>
                    <measurement group_id="O2" value="2.58" spread="7.01"/>
                    <measurement group_id="O3" value="0.83" spread="5.91"/>
                    <measurement group_id="O4" value="2.50" spread="5.59"/>
                    <measurement group_id="O5" value="-4.42" spread="12.73"/>
                    <measurement group_id="O6" value="2.67" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="5.64"/>
                    <measurement group_id="O2" value="-1.83" spread="10.52"/>
                    <measurement group_id="O3" value="-4.33" spread="5.82"/>
                    <measurement group_id="O4" value="-0.25" spread="7.62"/>
                    <measurement group_id="O5" value="-3.33" spread="8.30"/>
                    <measurement group_id="O6" value="-2.17" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="7.98"/>
                    <measurement group_id="O2" value="-2.58" spread="10.12"/>
                    <measurement group_id="O3" value="-1.75" spread="6.33"/>
                    <measurement group_id="O4" value="0.00" spread="6.75"/>
                    <measurement group_id="O5" value="0.42" spread="12.46"/>
                    <measurement group_id="O6" value="-3.58" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="5.48"/>
                    <measurement group_id="O2" value="-1.17" spread="12.30"/>
                    <measurement group_id="O3" value="-2.33" spread="8.68"/>
                    <measurement group_id="O4" value="0.17" spread="4.69"/>
                    <measurement group_id="O5" value="1.75" spread="10.11"/>
                    <measurement group_id="O6" value="3.25" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="5.83"/>
                    <measurement group_id="O2" value="2.00" spread="9.70"/>
                    <measurement group_id="O3" value="-0.08" spread="8.63"/>
                    <measurement group_id="O4" value="2.92" spread="11.59"/>
                    <measurement group_id="O5" value="-2.25" spread="11.49"/>
                    <measurement group_id="O6" value="-2.08" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="3.93"/>
                    <measurement group_id="O2" value="0.25" spread="10.12"/>
                    <measurement group_id="O3" value="-1.50" spread="10.11"/>
                    <measurement group_id="O4" value="-2.17" spread="7.81"/>
                    <measurement group_id="O5" value="-0.17" spread="7.75"/>
                    <measurement group_id="O6" value="0.42" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4 Hours Post-dose; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="5.00"/>
                    <measurement group_id="O2" value="0.90" spread="11.06"/>
                    <measurement group_id="O3" value="-5.75" spread="4.26"/>
                    <measurement group_id="O4" value="-2.58" spread="7.39"/>
                    <measurement group_id="O5" value="3.83" spread="9.11"/>
                    <measurement group_id="O6" value="-0.08" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="4.34"/>
                    <measurement group_id="O2" value="4.00" spread="5.28"/>
                    <measurement group_id="O3" value="6.17" spread="9.68"/>
                    <measurement group_id="O4" value="4.00" spread="6.57"/>
                    <measurement group_id="O5" value="5.58" spread="8.03"/>
                    <measurement group_id="O6" value="7.67" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="8.77"/>
                    <measurement group_id="O2" value="0.00" spread="6.67"/>
                    <measurement group_id="O3" value="4.25" spread="4.41"/>
                    <measurement group_id="O4" value="10.58" spread="8.44"/>
                    <measurement group_id="O5" value="5.83" spread="13.14"/>
                    <measurement group_id="O6" value="6.92" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Body Temperature in Cohort 1 and Cohort 3</title>
        <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Body Temperature in Cohort 1 and Cohort 3</title>
          <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-0.22" spread="0.43"/>
                    <measurement group_id="O4" value="-0.15" spread="0.31"/>
                    <measurement group_id="O5" value="-0.12" spread="0.34"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                    <measurement group_id="O7" value="-0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-0.22" spread="0.43"/>
                    <measurement group_id="O4" value="-0.15" spread="0.31"/>
                    <measurement group_id="O5" value="-0.12" spread="0.34"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                    <measurement group_id="O7" value="-0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-0.22" spread="0.43"/>
                    <measurement group_id="O4" value="-0.15" spread="0.31"/>
                    <measurement group_id="O5" value="-0.12" spread="0.34"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                    <measurement group_id="O7" value="-0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.38"/>
                    <measurement group_id="O2" value="-0.13" spread="0.37"/>
                    <measurement group_id="O3" value="-0.27" spread="0.28"/>
                    <measurement group_id="O4" value="-0.30" spread="0.42"/>
                    <measurement group_id="O5" value="-0.58" spread="0.30"/>
                    <measurement group_id="O6" value="-0.22" spread="0.29"/>
                    <measurement group_id="O7" value="0.00" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.41"/>
                    <measurement group_id="O2" value="-0.18" spread="0.26"/>
                    <measurement group_id="O3" value="-0.45" spread="0.58"/>
                    <measurement group_id="O4" value="0.00" spread="0.49"/>
                    <measurement group_id="O5" value="-0.16" spread="0.59"/>
                    <measurement group_id="O6" value="0.10" spread="0.48"/>
                    <measurement group_id="O7" value="0.26" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Body Temperature in Cohort 2</title>
        <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (1, 4, 12 Hours Post-dose), Day 2 and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Body Temperature in Cohort 2</title>
          <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1 Hour Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-0.10" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-0.10" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 12 Hours Post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-0.10" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.07"/>
                    <measurement group_id="O2" value="-0.15" spread="0.21"/>
                    <measurement group_id="O3" value="-0.33" spread="0.73"/>
                    <measurement group_id="O4" value="0.03" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.14"/>
                    <measurement group_id="O2" value="-0.35" spread="0.07"/>
                    <measurement group_id="O3" value="-0.10" spread="0.49"/>
                    <measurement group_id="O4" value="-0.22" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Body Temperature</title>
        <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Pre-dose on Day 1), Day 1 (4 Hours Post-dose), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7 (Pre-dose, 4 Hours Post-dose), Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14 (Pre-dose, 4 Hours Post-dose), Day 15, Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Body Temperature</title>
          <description>Body temperature of participants was measured at indicated time points in a supine position after 5 minutes rest. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 4 Hours Post dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.32"/>
                    <measurement group_id="O2" value="-0.03" spread="0.37"/>
                    <measurement group_id="O3" value="0.05" spread="0.30"/>
                    <measurement group_id="O4" value="-0.02" spread="0.43"/>
                    <measurement group_id="O5" value="0.13" spread="0.47"/>
                    <measurement group_id="O6" value="-0.20" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.55"/>
                    <measurement group_id="O2" value="-0.10" spread="0.15"/>
                    <measurement group_id="O3" value="0.05" spread="0.49"/>
                    <measurement group_id="O4" value="0.45" spread="0.33"/>
                    <measurement group_id="O5" value="0.13" spread="0.52"/>
                    <measurement group_id="O6" value="0.03" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.31"/>
                    <measurement group_id="O2" value="-0.10" spread="0.36"/>
                    <measurement group_id="O3" value="-0.07" spread="0.49"/>
                    <measurement group_id="O4" value="0.05" spread="0.20"/>
                    <measurement group_id="O5" value="0.07" spread="0.35"/>
                    <measurement group_id="O6" value="0.03" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.32"/>
                    <measurement group_id="O2" value="0.18" spread="0.13"/>
                    <measurement group_id="O3" value="0.23" spread="0.38"/>
                    <measurement group_id="O4" value="0.05" spread="0.21"/>
                    <measurement group_id="O5" value="0.27" spread="0.38"/>
                    <measurement group_id="O6" value="-0.45" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.51"/>
                    <measurement group_id="O2" value="0.33" spread="0.28"/>
                    <measurement group_id="O3" value="-0.05" spread="0.48"/>
                    <measurement group_id="O4" value="0.53" spread="0.21"/>
                    <measurement group_id="O5" value="0.13" spread="0.57"/>
                    <measurement group_id="O6" value="0.05" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.45"/>
                    <measurement group_id="O2" value="0.12" spread="0.30"/>
                    <measurement group_id="O3" value="0.08" spread="0.38"/>
                    <measurement group_id="O4" value="0.23" spread="0.18"/>
                    <measurement group_id="O5" value="0.02" spread="0.29"/>
                    <measurement group_id="O6" value="-0.08" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 Hours Post-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.45"/>
                    <measurement group_id="O2" value="0.12" spread="0.30"/>
                    <measurement group_id="O3" value="0.08" spread="0.38"/>
                    <measurement group_id="O4" value="0.23" spread="0.18"/>
                    <measurement group_id="O5" value="0.02" spread="0.29"/>
                    <measurement group_id="O6" value="-0.08" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.34"/>
                    <measurement group_id="O2" value="-0.02" spread="0.34"/>
                    <measurement group_id="O3" value="0.40" spread="0.37"/>
                    <measurement group_id="O4" value="0.08" spread="0.56"/>
                    <measurement group_id="O5" value="0.02" spread="0.54"/>
                    <measurement group_id="O6" value="-0.15" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.40"/>
                    <measurement group_id="O2" value="0.15" spread="0.32"/>
                    <measurement group_id="O3" value="0.30" spread="0.23"/>
                    <measurement group_id="O4" value="0.15" spread="0.39"/>
                    <measurement group_id="O5" value="0.23" spread="0.45"/>
                    <measurement group_id="O6" value="-0.20" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.51"/>
                    <measurement group_id="O2" value="0.17" spread="0.26"/>
                    <measurement group_id="O3" value="0.08" spread="0.45"/>
                    <measurement group_id="O4" value="-0.10" spread="0.49"/>
                    <measurement group_id="O5" value="-0.48" spread="0.60"/>
                    <measurement group_id="O6" value="-0.02" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.47"/>
                    <measurement group_id="O2" value="0.05" spread="0.39"/>
                    <measurement group_id="O3" value="-0.02" spread="0.38"/>
                    <measurement group_id="O4" value="0.07" spread="0.42"/>
                    <measurement group_id="O5" value="0.00" spread="0.50"/>
                    <measurement group_id="O6" value="-0.02" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.67"/>
                    <measurement group_id="O2" value="0.00" spread="0.39"/>
                    <measurement group_id="O3" value="-0.23" spread="0.45"/>
                    <measurement group_id="O4" value="0.55" spread="0.26"/>
                    <measurement group_id="O5" value="-0.07" spread="0.45"/>
                    <measurement group_id="O6" value="-0.08" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.42"/>
                    <measurement group_id="O2" value="0.03" spread="0.37"/>
                    <measurement group_id="O3" value="0.15" spread="0.48"/>
                    <measurement group_id="O4" value="-0.08" spread="0.18"/>
                    <measurement group_id="O5" value="0.05" spread="0.38"/>
                    <measurement group_id="O6" value="-0.12" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Pre-dose; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.45"/>
                    <measurement group_id="O2" value="0.48" spread="0.31"/>
                    <measurement group_id="O3" value="0.27" spread="0.44"/>
                    <measurement group_id="O4" value="0.25" spread="0.31"/>
                    <measurement group_id="O5" value="-0.10" spread="0.31"/>
                    <measurement group_id="O6" value="-0.12" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4 Hours Post-dose; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.45"/>
                    <measurement group_id="O2" value="0.42" spread="0.29"/>
                    <measurement group_id="O3" value="0.27" spread="0.44"/>
                    <measurement group_id="O4" value="0.25" spread="0.31"/>
                    <measurement group_id="O5" value="-0.10" spread="0.31"/>
                    <measurement group_id="O6" value="-0.12" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.35"/>
                    <measurement group_id="O2" value="0.10" spread="0.24"/>
                    <measurement group_id="O3" value="0.47" spread="0.46"/>
                    <measurement group_id="O4" value="0.30" spread="0.55"/>
                    <measurement group_id="O5" value="0.28" spread="0.47"/>
                    <measurement group_id="O6" value="0.03" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,5,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.58"/>
                    <measurement group_id="O2" value="0.17" spread="0.52"/>
                    <measurement group_id="O3" value="0.24" spread="0.61"/>
                    <measurement group_id="O4" value="0.68" spread="0.34"/>
                    <measurement group_id="O5" value="0.47" spread="0.32"/>
                    <measurement group_id="O6" value="0.08" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Different Stool Types Assessed Using Bristol Stool Form Scale (BSFS) in Cohort 1</title>
        <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
        <time_frame>Up to 64 days in Cohort 1</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 orally in one of the Periods of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Different Stool Types Assessed Using Bristol Stool Form Scale (BSFS) in Cohort 1</title>
          <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 2</title>
        <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
        <time_frame>Up to 30 days in Cohort 2</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 2</title>
          <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 3</title>
        <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
        <time_frame>Up to 30 days in Cohort 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 3</title>
          <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Average BSFS at Indicated Time Points</title>
        <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
        <time_frame>Day -1, Days 1-3, Days 4-7, Days 1-7, Days 8-14</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Average BSFS at Indicated Time Points</title>
          <description>The BSFS describes 7 types of stool as following; Type 1-Separate hard lumps (hard to pass), Type 2-Sausage-shaped but lumpy, Type 3-Like a sausage but cracks on surface, Type 4-Like a sausage or snake, smooth and soft, Type 5- Soft blobs with clear cut edges, Type-6 Fluffy pieces with ragged edges, a mushy stool, and Type 7-Watery, no solid pieces (entirely liquid). BSFS was used by the participants during the study to capture the quality of stool using a 7-point scale ranging from Type 1=separate hard lumps like nuts (difficult to pass) to 7= watery, no solid pieces (entirely liquid).</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1; n=7,4, 6,6,4,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="1.30"/>
                    <measurement group_id="O2" value="3.88" spread="0.63"/>
                    <measurement group_id="O3" value="3.92" spread="0.49"/>
                    <measurement group_id="O4" value="3.92" spread="1.43"/>
                    <measurement group_id="O5" value="4.13" spread="1.03"/>
                    <measurement group_id="O6" value="4.30" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-3; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.14"/>
                    <measurement group_id="O2" value="3.55" spread="1.57"/>
                    <measurement group_id="O3" value="3.97" spread="1.06"/>
                    <measurement group_id="O4" value="3.62" spread="0.71"/>
                    <measurement group_id="O5" value="3.75" spread="1.33"/>
                    <measurement group_id="O6" value="3.37" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 4-7;n=9,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="1.14"/>
                    <measurement group_id="O2" value="3.78" spread="1.30"/>
                    <measurement group_id="O3" value="3.68" spread="1.14"/>
                    <measurement group_id="O4" value="3.37" spread="0.47"/>
                    <measurement group_id="O5" value="3.85" spread="0.95"/>
                    <measurement group_id="O6" value="3.45" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-7;n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="0.99"/>
                    <measurement group_id="O2" value="3.75" spread="1.36"/>
                    <measurement group_id="O3" value="3.77" spread="0.86"/>
                    <measurement group_id="O4" value="3.48" spread="0.50"/>
                    <measurement group_id="O5" value="3.78" spread="1.08"/>
                    <measurement group_id="O6" value="3.38" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 8-14;n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="0.97"/>
                    <measurement group_id="O2" value="3.63" spread="1.12"/>
                    <measurement group_id="O3" value="3.93" spread="0.77"/>
                    <measurement group_id="O4" value="3.10" spread="0.63"/>
                    <measurement group_id="O5" value="3.63" spread="1.29"/>
                    <measurement group_id="O6" value="3.48" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 1 and Cohort 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 1 and Cohort 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.06"/>
                    <measurement group_id="O3" value="0.02" spread="0.04"/>
                    <measurement group_id="O4" value="0.00" spread="0.06"/>
                    <measurement group_id="O5" value="0.04" spread="0.05"/>
                    <measurement group_id="O6" value="-0.03" spread="0.05"/>
                    <measurement group_id="O7" value="-0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.08"/>
                    <measurement group_id="O3" value="0.05" spread="0.14"/>
                    <measurement group_id="O4" value="-0.03" spread="0.05"/>
                    <measurement group_id="O5" value="0.02" spread="0.05"/>
                    <measurement group_id="O6" value="0.02" spread="0.04"/>
                    <measurement group_id="O7" value="0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.40"/>
                    <measurement group_id="O2" value="-0.10" spread="0.40"/>
                    <measurement group_id="O3" value="-0.32" spread="0.46"/>
                    <measurement group_id="O4" value="-0.43" spread="0.36"/>
                    <measurement group_id="O5" value="-0.50" spread="0.34"/>
                    <measurement group_id="O6" value="0.03" spread="0.31"/>
                    <measurement group_id="O7" value="-0.16" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.12"/>
                    <measurement group_id="O2" value="-0.08" spread="0.10"/>
                    <measurement group_id="O3" value="-0.13" spread="0.08"/>
                    <measurement group_id="O4" value="-0.08" spread="0.12"/>
                    <measurement group_id="O5" value="-0.04" spread="0.21"/>
                    <measurement group_id="O6" value="0.03" spread="0.08"/>
                    <measurement group_id="O7" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.05"/>
                    <measurement group_id="O2" value="-0.73" spread="1.06"/>
                    <measurement group_id="O3" value="-0.60" spread="1.55"/>
                    <measurement group_id="O4" value="-0.23" spread="0.70"/>
                    <measurement group_id="O5" value="-0.16" spread="2.76"/>
                    <measurement group_id="O6" value="-0.60" spread="0.85"/>
                    <measurement group_id="O7" value="-0.36" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="34.6"/>
                    <measurement group_id="O2" value="-4.8" spread="34.1"/>
                    <measurement group_id="O3" value="-22.5" spread="45.6"/>
                    <measurement group_id="O4" value="2.2" spread="32.4"/>
                    <measurement group_id="O5" value="-8.0" spread="43.7"/>
                    <measurement group_id="O6" value="-23.3" spread="13.9"/>
                    <measurement group_id="O7" value="-46.6" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes ;Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="1.06"/>
                    <measurement group_id="O2" value="-0.88" spread="0.95"/>
                    <measurement group_id="O3" value="-0.95" spread="1.33"/>
                    <measurement group_id="O4" value="-0.82" spread="0.80"/>
                    <measurement group_id="O5" value="-0.58" spread="2.64"/>
                    <measurement group_id="O6" value="-0.53" spread="0.94"/>
                    <measurement group_id="O7" value="-0.52" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.08"/>
                    <measurement group_id="O2" value="0.05" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.06"/>
                    <measurement group_id="O4" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.14"/>
                    <measurement group_id="O2" value="0.10" spread="0.14"/>
                    <measurement group_id="O3" value="0.25" spread="0.65"/>
                    <measurement group_id="O4" value="0.12" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.07"/>
                    <measurement group_id="O2" value="-0.05" spread="0.07"/>
                    <measurement group_id="O3" value="-0.02" spread="0.15"/>
                    <measurement group_id="O4" value="-0.08" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.42"/>
                    <measurement group_id="O2" value="-0.85" spread="0.35"/>
                    <measurement group_id="O3" value="-1.25" spread="1.97"/>
                    <measurement group_id="O4" value="-1.73" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="11.3"/>
                    <measurement group_id="O2" value="-45.0" spread="26.9"/>
                    <measurement group_id="O3" value="-7.2" spread="5.9"/>
                    <measurement group_id="O4" value="-29.2" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes ;Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.57"/>
                    <measurement group_id="O2" value="-0.75" spread="0.35"/>
                    <measurement group_id="O3" value="-1.00" spread="2.44"/>
                    <measurement group_id="O4" value="-1.68" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes</title>
        <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes</title>
          <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.00" spread="0.06"/>
                    <measurement group_id="O3" value="0.05" spread="0.05"/>
                    <measurement group_id="O4" value="0.03" spread="0.05"/>
                    <measurement group_id="O5" value="0.02" spread="0.04"/>
                    <measurement group_id="O6" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.04" spread="0.05"/>
                    <measurement group_id="O3" value="0.05" spread="0.05"/>
                    <measurement group_id="O4" value="0.05" spread="0.05"/>
                    <measurement group_id="O5" value="0.03" spread="0.05"/>
                    <measurement group_id="O6" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Follow-up (Day 25) ; n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.06"/>
                    <measurement group_id="O3" value="0.06" spread="0.05"/>
                    <measurement group_id="O4" value="0.05" spread="0.05"/>
                    <measurement group_id="O5" value="0.02" spread="0.07"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.09"/>
                    <measurement group_id="O2" value="0.03" spread="0.05"/>
                    <measurement group_id="O3" value="-0.02" spread="0.04"/>
                    <measurement group_id="O4" value="0.03" spread="0.08"/>
                    <measurement group_id="O5" value="0.05" spread="0.05"/>
                    <measurement group_id="O6" value="0.04" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.10"/>
                    <measurement group_id="O2" value="0.04" spread="0.11"/>
                    <measurement group_id="O3" value="0.02" spread="0.04"/>
                    <measurement group_id="O4" value="0.03" spread="0.08"/>
                    <measurement group_id="O5" value="0.05" spread="0.05"/>
                    <measurement group_id="O6" value="-0.03" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.09"/>
                    <measurement group_id="O2" value="0.05" spread="0.09"/>
                    <measurement group_id="O3" value="0.04" spread="0.05"/>
                    <measurement group_id="O4" value="0.03" spread="0.10"/>
                    <measurement group_id="O5" value="0.05" spread="0.08"/>
                    <measurement group_id="O6" value="-0.03" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 7 ;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.35"/>
                    <measurement group_id="O2" value="-0.35" spread="0.26"/>
                    <measurement group_id="O3" value="-0.18" spread="0.24"/>
                    <measurement group_id="O4" value="-0.10" spread="0.30"/>
                    <measurement group_id="O5" value="0.23" spread="0.19"/>
                    <measurement group_id="O6" value="-0.22" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 15; n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.32"/>
                    <measurement group_id="O2" value="0.02" spread="0.22"/>
                    <measurement group_id="O3" value="0.10" spread="0.20"/>
                    <measurement group_id="O4" value="-0.05" spread="0.36"/>
                    <measurement group_id="O5" value="0.40" spread="0.25"/>
                    <measurement group_id="O6" value="-0.10" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.25"/>
                    <measurement group_id="O2" value="-0.12" spread="0.33"/>
                    <measurement group_id="O3" value="0.25" spread="0.35"/>
                    <measurement group_id="O4" value="0.00" spread="0.13"/>
                    <measurement group_id="O5" value="0.07" spread="0.23"/>
                    <measurement group_id="O6" value="-0.32" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.09"/>
                    <measurement group_id="O2" value="-0.03" spread="0.05"/>
                    <measurement group_id="O3" value="-0.08" spread="0.12"/>
                    <measurement group_id="O4" value="-0.10" spread="0.06"/>
                    <measurement group_id="O5" value="0.05" spread="0.10"/>
                    <measurement group_id="O6" value="0.02" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.11"/>
                    <measurement group_id="O2" value="-0.02" spread="0.04"/>
                    <measurement group_id="O3" value="-0.02" spread="0.08"/>
                    <measurement group_id="O4" value="-0.10" spread="0.09"/>
                    <measurement group_id="O5" value="0.05" spread="0.05"/>
                    <measurement group_id="O6" value="-0.07" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.12"/>
                    <measurement group_id="O2" value="-0.05" spread="0.10"/>
                    <measurement group_id="O3" value="0.03" spread="0.08"/>
                    <measurement group_id="O4" value="-0.10" spread="0.06"/>
                    <measurement group_id="O5" value="0.17" spread="0.27"/>
                    <measurement group_id="O6" value="-0.07" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.05"/>
                    <measurement group_id="O2" value="0.05" spread="0.57"/>
                    <measurement group_id="O3" value="-0.42" spread="0.34"/>
                    <measurement group_id="O4" value="-0.65" spread="0.98"/>
                    <measurement group_id="O5" value="-0.82" spread="0.79"/>
                    <measurement group_id="O6" value="-0.88" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.74"/>
                    <measurement group_id="O2" value="-0.02" spread="0.39"/>
                    <measurement group_id="O3" value="-0.22" spread="0.77"/>
                    <measurement group_id="O4" value="-0.72" spread="0.87"/>
                    <measurement group_id="O5" value="-0.58" spread="0.50"/>
                    <measurement group_id="O6" value="-0.95" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.94"/>
                    <measurement group_id="O2" value="0.05" spread="0.42"/>
                    <measurement group_id="O3" value="0.07" spread="0.66"/>
                    <measurement group_id="O4" value="-0.37" spread="1.33"/>
                    <measurement group_id="O5" value="0.73" spread="3.34"/>
                    <measurement group_id="O6" value="-0.58" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="25.0"/>
                    <measurement group_id="O2" value="9.7" spread="21.9"/>
                    <measurement group_id="O3" value="8.3" spread="20.8"/>
                    <measurement group_id="O4" value="26.7" spread="12.1"/>
                    <measurement group_id="O5" value="-11.0" spread="12.1"/>
                    <measurement group_id="O6" value="4.5" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="28.5"/>
                    <measurement group_id="O2" value="24.2" spread="26.7"/>
                    <measurement group_id="O3" value="-3.0" spread="23.9"/>
                    <measurement group_id="O4" value="3.7" spread="16.6"/>
                    <measurement group_id="O5" value="7.3" spread="25.5"/>
                    <measurement group_id="O6" value="7.5" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="34.5"/>
                    <measurement group_id="O2" value="37.3" spread="24.3"/>
                    <measurement group_id="O3" value="26.2" spread="24.2"/>
                    <measurement group_id="O4" value="27.3" spread="37.0"/>
                    <measurement group_id="O5" value="2.5" spread="20.9"/>
                    <measurement group_id="O6" value="2.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 7;n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="1.13"/>
                    <measurement group_id="O2" value="-0.32" spread="0.52"/>
                    <measurement group_id="O3" value="-0.65" spread="0.60"/>
                    <measurement group_id="O4" value="-0.82" spread="1.00"/>
                    <measurement group_id="O5" value="-0.53" spread="0.92"/>
                    <measurement group_id="O6" value="-1.08" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes ;Day 15;n=10, 5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.79"/>
                    <measurement group_id="O2" value="0.10" spread="0.47"/>
                    <measurement group_id="O3" value="-0.13" spread="0.76"/>
                    <measurement group_id="O4" value="-0.82" spread="0.85"/>
                    <measurement group_id="O5" value="-0.08" spread="0.45"/>
                    <measurement group_id="O6" value="-1.10" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Follow-up (Day 25); n=10, 6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.72"/>
                    <measurement group_id="O2" value="-0.12" spread="0.59"/>
                    <measurement group_id="O3" value="0.43" spread="0.88"/>
                    <measurement group_id="O4" value="-0.45" spread="1.24"/>
                    <measurement group_id="O5" value="0.98" spread="3.38"/>
                    <measurement group_id="O6" value="-1.00" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythrocytes in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythrocytes in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.260"/>
                    <measurement group_id="O2" value="0.275" spread="0.321"/>
                    <measurement group_id="O3" value="-0.073" spread="0.310"/>
                    <measurement group_id="O4" value="0.112" spread="0.390"/>
                    <measurement group_id="O5" value="0.120" spread="0.373"/>
                    <measurement group_id="O6" value="0.063" spread="0.094"/>
                    <measurement group_id="O7" value="-0.132" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythrocytes in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythrocytes in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" spread="0.156"/>
                    <measurement group_id="O2" value="0.150" spread="0.269"/>
                    <measurement group_id="O3" value="0.167" spread="0.118"/>
                    <measurement group_id="O4" value="0.042" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Erythrocytes</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Erythrocytes</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.250"/>
                    <measurement group_id="O2" value="0.208" spread="0.119"/>
                    <measurement group_id="O3" value="0.033" spread="0.060"/>
                    <measurement group_id="O4" value="0.230" spread="0.145"/>
                    <measurement group_id="O5" value="-0.183" spread="0.183"/>
                    <measurement group_id="O6" value="-0.023" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" spread="0.258"/>
                    <measurement group_id="O2" value="0.334" spread="0.235"/>
                    <measurement group_id="O3" value="0.270" spread="0.190"/>
                    <measurement group_id="O4" value="0.302" spread="0.179"/>
                    <measurement group_id="O5" value="0.162" spread="0.252"/>
                    <measurement group_id="O6" value="0.082" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.355"/>
                    <measurement group_id="O2" value="0.287" spread="0.256"/>
                    <measurement group_id="O3" value="0.155" spread="0.182"/>
                    <measurement group_id="O4" value="0.158" spread="0.239"/>
                    <measurement group_id="O5" value="-0.195" spread="0.165"/>
                    <measurement group_id="O6" value="-0.227" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hemoglobin in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hemoglobin in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="8.3"/>
                    <measurement group_id="O2" value="6.2" spread="9.0"/>
                    <measurement group_id="O3" value="-2.5" spread="9.3"/>
                    <measurement group_id="O4" value="2.0" spread="9.0"/>
                    <measurement group_id="O5" value="-0.8" spread="8.8"/>
                    <measurement group_id="O6" value="2.2" spread="4.3"/>
                    <measurement group_id="O7" value="-1.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hemoglobin in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hemoglobin in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.8"/>
                    <measurement group_id="O2" value="5.5" spread="9.2"/>
                    <measurement group_id="O3" value="5.8" spread="3.3"/>
                    <measurement group_id="O4" value="2.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Hemoglobin</title>
        <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Hemoglobin</title>
          <description>Blood samples were collected for analysis of hematology parameters including hemoglobin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="6.5"/>
                    <measurement group_id="O2" value="1.8" spread="4.5"/>
                    <measurement group_id="O3" value="-5.3" spread="2.0"/>
                    <measurement group_id="O4" value="0.7" spread="4.1"/>
                    <measurement group_id="O5" value="-6.7" spread="4.3"/>
                    <measurement group_id="O6" value="0.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="8.7"/>
                    <measurement group_id="O2" value="6.4" spread="6.7"/>
                    <measurement group_id="O3" value="1.3" spread="5.6"/>
                    <measurement group_id="O4" value="3.7" spread="5.4"/>
                    <measurement group_id="O5" value="2.2" spread="4.9"/>
                    <measurement group_id="O6" value="3.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.4"/>
                    <measurement group_id="O2" value="4.3" spread="7.1"/>
                    <measurement group_id="O3" value="-1.8" spread="5.6"/>
                    <measurement group_id="O4" value="-0.3" spread="5.9"/>
                    <measurement group_id="O5" value="-3.5" spread="4.5"/>
                    <measurement group_id="O6" value="-3.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) in Cohort 1 and Cohort 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) in Cohort 1 and Cohort 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="0.2" spread="1.5"/>
                    <measurement group_id="O3" value="1.5" spread="0.8"/>
                    <measurement group_id="O4" value="1.7" spread="1.2"/>
                    <measurement group_id="O5" value="1.6" spread="1.1"/>
                    <measurement group_id="O6" value="0.8" spread="0.8"/>
                    <measurement group_id="O7" value="1.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythrocyte MCV in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythrocyte MCV in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.4"/>
                    <measurement group_id="O2" value="-2.0" spread="1.4"/>
                    <measurement group_id="O3" value="1.5" spread="3.0"/>
                    <measurement group_id="O4" value="0.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Erythrocyte MCV</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Erythrocyte MCV</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythrocyte MCV. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.6"/>
                    <measurement group_id="O2" value="0.2" spread="1.2"/>
                    <measurement group_id="O3" value="-2.7" spread="1.8"/>
                    <measurement group_id="O4" value="-0.2" spread="0.8"/>
                    <measurement group_id="O5" value="0.2" spread="1.2"/>
                    <measurement group_id="O6" value="-1.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.2"/>
                    <measurement group_id="O2" value="0.2" spread="1.9"/>
                    <measurement group_id="O3" value="-2.2" spread="1.7"/>
                    <measurement group_id="O4" value="-0.3" spread="1.4"/>
                    <measurement group_id="O5" value="0.8" spread="1.2"/>
                    <measurement group_id="O6" value="-0.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.9"/>
                    <measurement group_id="O2" value="0.0" spread="1.4"/>
                    <measurement group_id="O3" value="-1.5" spread="1.9"/>
                    <measurement group_id="O4" value="0.3" spread="0.8"/>
                    <measurement group_id="O5" value="1.8" spread="0.4"/>
                    <measurement group_id="O6" value="0.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythorocyte Mean Corpuscular Hemoglobin (MCH) in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythorocyte Mean Corpuscular Hemoglobin (MCH) in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Picogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.71"/>
                    <measurement group_id="O2" value="-0.37" spread="0.47"/>
                    <measurement group_id="O3" value="-0.13" spread="0.40"/>
                    <measurement group_id="O4" value="-0.25" spread="0.66"/>
                    <measurement group_id="O5" value="-0.84" spread="0.52"/>
                    <measurement group_id="O6" value="0.08" spread="0.35"/>
                    <measurement group_id="O7" value="0.54" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Erythrocyte MCH in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Erythrocyte MCH in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Picogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.28"/>
                    <measurement group_id="O2" value="0.20" spread="0.28"/>
                    <measurement group_id="O3" value="0.20" spread="0.37"/>
                    <measurement group_id="O4" value="0.27" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Erythrocyte MCH</title>
        <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Erythrocyte MCH</title>
          <description>Blood samples were collected for analysis of hematology parameters including Erythorocyte MCH. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Picogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.55"/>
                    <measurement group_id="O2" value="-0.87" spread="0.37"/>
                    <measurement group_id="O3" value="-1.25" spread="0.40"/>
                    <measurement group_id="O4" value="-1.13" spread="0.21"/>
                    <measurement group_id="O5" value="-0.28" spread="0.34"/>
                    <measurement group_id="O6" value="0.13" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.72"/>
                    <measurement group_id="O2" value="-0.70" spread="0.37"/>
                    <measurement group_id="O3" value="-1.33" spread="0.14"/>
                    <measurement group_id="O4" value="-0.95" spread="0.38"/>
                    <measurement group_id="O5" value="-0.50" spread="0.46"/>
                    <measurement group_id="O6" value="0.23" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.57"/>
                    <measurement group_id="O2" value="-0.78" spread="0.58"/>
                    <measurement group_id="O3" value="-1.30" spread="0.25"/>
                    <measurement group_id="O4" value="-0.98" spread="0.26"/>
                    <measurement group_id="O5" value="0.47" spread="0.39"/>
                    <measurement group_id="O6" value="0.77" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hematocrit in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hematocrit in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.021"/>
                    <measurement group_id="O2" value="0.025" spread="0.027"/>
                    <measurement group_id="O3" value="0.002" spread="0.029"/>
                    <measurement group_id="O4" value="0.017" spread="0.031"/>
                    <measurement group_id="O5" value="0.018" spread="0.026"/>
                    <measurement group_id="O6" value="0.007" spread="0.008"/>
                    <measurement group_id="O7" value="-0.008" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hematocrit in Cohort 2</title>
        <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hematocrit in Cohort 2</title>
          <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.021"/>
                    <measurement group_id="O2" value="0.010" spread="0.028"/>
                    <measurement group_id="O3" value="0.023" spread="0.020"/>
                    <measurement group_id="O4" value="0.008" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Hematocrit</title>
        <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Hematocrit</title>
          <description>Blood samples were collected for analysis of hematology parameters including Hematocrit. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.029"/>
                    <measurement group_id="O2" value="0.018" spread="0.010"/>
                    <measurement group_id="O3" value="-0.012" spread="0.012"/>
                    <measurement group_id="O4" value="0.018" spread="0.013"/>
                    <measurement group_id="O5" value="-0.017" spread="0.014"/>
                    <measurement group_id="O6" value="-0.007" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.025"/>
                    <measurement group_id="O2" value="0.030" spread="0.025"/>
                    <measurement group_id="O3" value="0.015" spread="0.018"/>
                    <measurement group_id="O4" value="0.025" spread="0.016"/>
                    <measurement group_id="O5" value="0.017" spread="0.019"/>
                    <measurement group_id="O6" value="0.005" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.032"/>
                    <measurement group_id="O2" value="0.025" spread="0.021"/>
                    <measurement group_id="O3" value="0.005" spread="0.016"/>
                    <measurement group_id="O4" value="0.017" spread="0.020"/>
                    <measurement group_id="O5" value="-0.008" spread="0.015"/>
                    <measurement group_id="O6" value="-0.020" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST), Alkaline Phosphatase (Alk Phos) in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST), Alkaline Phosphatase (Alk Phos) in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="27.1"/>
                    <measurement group_id="O2" value="-1.8" spread="15.0"/>
                    <measurement group_id="O3" value="-6.2" spread="12.4"/>
                    <measurement group_id="O4" value="-1.2" spread="14.2"/>
                    <measurement group_id="O5" value="-7.2" spread="15.6"/>
                    <measurement group_id="O6" value="6.0" spread="3.2"/>
                    <measurement group_id="O7" value="8.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="10.3"/>
                    <measurement group_id="O2" value="1.0" spread="8.1"/>
                    <measurement group_id="O3" value="-0.2" spread="5.3"/>
                    <measurement group_id="O4" value="-0.2" spread="5.3"/>
                    <measurement group_id="O5" value="-1.8" spread="4.7"/>
                    <measurement group_id="O6" value="-5.0" spread="5.2"/>
                    <measurement group_id="O7" value="-3.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="11.7"/>
                    <measurement group_id="O2" value="-7.3" spread="7.5"/>
                    <measurement group_id="O3" value="-9.2" spread="8.9"/>
                    <measurement group_id="O4" value="-10.5" spread="8.7"/>
                    <measurement group_id="O5" value="-17.0" spread="6.6"/>
                    <measurement group_id="O6" value="0.2" spread="6.5"/>
                    <measurement group_id="O7" value="-3.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in ALT, AST and Alk Phos in Cohort 2</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in ALT, AST and Alk Phos in Cohort 2</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.7"/>
                    <measurement group_id="O2" value="-0.5" spread="2.1"/>
                    <measurement group_id="O3" value="0.2" spread="1.5"/>
                    <measurement group_id="O4" value="-2.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.7"/>
                    <measurement group_id="O2" value="-1.5" spread="2.1"/>
                    <measurement group_id="O3" value="-4.5" spread="3.3"/>
                    <measurement group_id="O4" value="-4.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="5.7"/>
                    <measurement group_id="O2" value="-10.0" spread="4.2"/>
                    <measurement group_id="O3" value="0.8" spread="5.8"/>
                    <measurement group_id="O4" value="-2.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in ALT, AST and Alk Phos</title>
        <description>Blood samples were collected for analysis of hematology parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in ALT, AST and Alk Phos</title>
          <description>Blood samples were collected for analysis of hematology parameters including ALT, AST and Alk Phos. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="10.9"/>
                    <measurement group_id="O2" value="-7.7" spread="5.9"/>
                    <measurement group_id="O3" value="-6.2" spread="6.0"/>
                    <measurement group_id="O4" value="2.3" spread="5.5"/>
                    <measurement group_id="O5" value="-0.8" spread="2.8"/>
                    <measurement group_id="O6" value="-0.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="11.9"/>
                    <measurement group_id="O2" value="-8.2" spread="4.7"/>
                    <measurement group_id="O3" value="-5.3" spread="8.1"/>
                    <measurement group_id="O4" value="-3.8" spread="6.7"/>
                    <measurement group_id="O5" value="-0.7" spread="4.1"/>
                    <measurement group_id="O6" value="-0.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="9.0"/>
                    <measurement group_id="O2" value="-7.8" spread="5.3"/>
                    <measurement group_id="O3" value="-9.3" spread="7.7"/>
                    <measurement group_id="O4" value="-1.0" spread="6.8"/>
                    <measurement group_id="O5" value="0.3" spread="7.6"/>
                    <measurement group_id="O6" value="-2.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST ; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="18.5"/>
                    <measurement group_id="O2" value="0.3" spread="4.5"/>
                    <measurement group_id="O3" value="3.5" spread="7.7"/>
                    <measurement group_id="O4" value="7.7" spread="6.1"/>
                    <measurement group_id="O5" value="3.0" spread="10.4"/>
                    <measurement group_id="O6" value="0.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.3"/>
                    <measurement group_id="O2" value="-1.6" spread="4.2"/>
                    <measurement group_id="O3" value="3.2" spread="6.7"/>
                    <measurement group_id="O4" value="0.5" spread="3.3"/>
                    <measurement group_id="O5" value="-0.8" spread="2.9"/>
                    <measurement group_id="O6" value="-0.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="4.0"/>
                    <measurement group_id="O2" value="-0.2" spread="5.5"/>
                    <measurement group_id="O3" value="1.7" spread="5.1"/>
                    <measurement group_id="O4" value="7.7" spread="16.0"/>
                    <measurement group_id="O5" value="1.2" spread="4.4"/>
                    <measurement group_id="O6" value="-1.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="4.4"/>
                    <measurement group_id="O2" value="-7.3" spread="9.4"/>
                    <measurement group_id="O3" value="-8.7" spread="4.9"/>
                    <measurement group_id="O4" value="-2.8" spread="6.6"/>
                    <measurement group_id="O5" value="-10.5" spread="5.6"/>
                    <measurement group_id="O6" value="-1.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos ; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="5.9"/>
                    <measurement group_id="O2" value="-1.4" spread="3.6"/>
                    <measurement group_id="O3" value="-5.3" spread="6.5"/>
                    <measurement group_id="O4" value="-0.5" spread="7.5"/>
                    <measurement group_id="O5" value="-4.8" spread="6.8"/>
                    <measurement group_id="O6" value="0.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos ; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="8.0"/>
                    <measurement group_id="O2" value="-7.8" spread="17.8"/>
                    <measurement group_id="O3" value="-6.2" spread="8.8"/>
                    <measurement group_id="O4" value="1.2" spread="12.4"/>
                    <measurement group_id="O5" value="-0.7" spread="7.1"/>
                    <measurement group_id="O6" value="0.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.3"/>
                    <measurement group_id="O2" value="1.0" spread="4.2"/>
                    <measurement group_id="O3" value="1.2" spread="3.0"/>
                    <measurement group_id="O4" value="2.2" spread="1.9"/>
                    <measurement group_id="O5" value="1.6" spread="3.4"/>
                    <measurement group_id="O6" value="-0.7" spread="4.4"/>
                    <measurement group_id="O7" value="2.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="7.0"/>
                    <measurement group_id="O2" value="-2.5" spread="5.3"/>
                    <measurement group_id="O3" value="-2.3" spread="8.5"/>
                    <measurement group_id="O4" value="1.7" spread="8.6"/>
                    <measurement group_id="O5" value="0.4" spread="11.1"/>
                    <measurement group_id="O6" value="1.5" spread="5.0"/>
                    <measurement group_id="O7" value="-3.0" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="1.49"/>
                    <measurement group_id="O2" value="0.85" spread="1.86"/>
                    <measurement group_id="O3" value="0.52" spread="0.74"/>
                    <measurement group_id="O4" value="1.38" spread="0.90"/>
                    <measurement group_id="O5" value="1.58" spread="1.00"/>
                    <measurement group_id="O6" value="-1.15" spread="1.84"/>
                    <measurement group_id="O7" value="-0.14" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 2</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 2</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.1"/>
                    <measurement group_id="O2" value="2.0" spread="1.4"/>
                    <measurement group_id="O3" value="1.5" spread="3.4"/>
                    <measurement group_id="O4" value="-0.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="7.8"/>
                    <measurement group_id="O2" value="-8.0" spread="8.5"/>
                    <measurement group_id="O3" value="-2.2" spread="4.6"/>
                    <measurement group_id="O4" value="-5.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.35"/>
                    <measurement group_id="O2" value="0.50" spread="0.00"/>
                    <measurement group_id="O3" value="0.38" spread="0.87"/>
                    <measurement group_id="O4" value="-0.10" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin</title>
        <description>Blood samples were collected for analysis of hematology parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin</title>
          <description>Blood samples were collected for analysis of hematology parameters including bilirubin, creatinine, and direct bilirubin. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.7"/>
                    <measurement group_id="O2" value="2.5" spread="1.9"/>
                    <measurement group_id="O3" value="3.2" spread="2.8"/>
                    <measurement group_id="O4" value="2.0" spread="1.7"/>
                    <measurement group_id="O5" value="2.0" spread="2.8"/>
                    <measurement group_id="O6" value="2.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.0"/>
                    <measurement group_id="O2" value="1.0" spread="2.4"/>
                    <measurement group_id="O3" value="2.5" spread="1.5"/>
                    <measurement group_id="O4" value="1.5" spread="1.6"/>
                    <measurement group_id="O5" value="2.3" spread="2.9"/>
                    <measurement group_id="O6" value="2.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Follow-up (Day 25);n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.6"/>
                    <measurement group_id="O2" value="0.5" spread="4.4"/>
                    <measurement group_id="O3" value="2.5" spread="2.2"/>
                    <measurement group_id="O4" value="1.8" spread="3.5"/>
                    <measurement group_id="O5" value="0.3" spread="4.4"/>
                    <measurement group_id="O6" value="0.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine ; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="6.5"/>
                    <measurement group_id="O2" value="-5.5" spread="14.0"/>
                    <measurement group_id="O3" value="-1.3" spread="15.7"/>
                    <measurement group_id="O4" value="-3.3" spread="7.3"/>
                    <measurement group_id="O5" value="-13.0" spread="9.2"/>
                    <measurement group_id="O6" value="-1.0" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="5.3"/>
                    <measurement group_id="O2" value="2.2" spread="12.7"/>
                    <measurement group_id="O3" value="-1.0" spread="15.3"/>
                    <measurement group_id="O4" value="-1.0" spread="7.8"/>
                    <measurement group_id="O5" value="-9.2" spread="13.2"/>
                    <measurement group_id="O6" value="-2.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="6.9"/>
                    <measurement group_id="O2" value="-1.0" spread="16.6"/>
                    <measurement group_id="O3" value="0.8" spread="15.0"/>
                    <measurement group_id="O4" value="0.5" spread="7.1"/>
                    <measurement group_id="O5" value="-4.0" spread="11.3"/>
                    <measurement group_id="O6" value="-1.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin ; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.43"/>
                    <measurement group_id="O2" value="1.30" spread="0.59"/>
                    <measurement group_id="O3" value="1.32" spread="1.22"/>
                    <measurement group_id="O4" value="1.22" spread="0.64"/>
                    <measurement group_id="O5" value="0.48" spread="1.15"/>
                    <measurement group_id="O6" value="0.63" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin ; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.67"/>
                    <measurement group_id="O2" value="1.10" spread="0.54"/>
                    <measurement group_id="O3" value="0.73" spread="0.81"/>
                    <measurement group_id="O4" value="1.73" spread="0.46"/>
                    <measurement group_id="O5" value="0.73" spread="1.17"/>
                    <measurement group_id="O6" value="0.25" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Follow-up(Day 25);n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.62"/>
                    <measurement group_id="O2" value="1.10" spread="1.05"/>
                    <measurement group_id="O3" value="0.95" spread="0.87"/>
                    <measurement group_id="O4" value="1.78" spread="1.06"/>
                    <measurement group_id="O5" value="-0.12" spread="1.42"/>
                    <measurement group_id="O6" value="0.48" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.108"/>
                    <measurement group_id="O2" value="-0.005" spread="0.134"/>
                    <measurement group_id="O3" value="-0.075" spread="0.107"/>
                    <measurement group_id="O4" value="-0.060" spread="0.145"/>
                    <measurement group_id="O5" value="-0.054" spread="0.152"/>
                    <measurement group_id="O6" value="-0.063" spread="0.038"/>
                    <measurement group_id="O7" value="-0.124" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.69"/>
                    <measurement group_id="O2" value="-0.03" spread="0.27"/>
                    <measurement group_id="O3" value="0.25" spread="0.82"/>
                    <measurement group_id="O4" value="0.22" spread="0.36"/>
                    <measurement group_id="O5" value="-0.32" spread="1.32"/>
                    <measurement group_id="O6" value="-0.23" spread="0.64"/>
                    <measurement group_id="O7" value="0.22" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.28"/>
                    <measurement group_id="O2" value="0.05" spread="0.30"/>
                    <measurement group_id="O3" value="0.13" spread="0.35"/>
                    <measurement group_id="O4" value="0.10" spread="0.23"/>
                    <measurement group_id="O5" value="-0.08" spread="0.16"/>
                    <measurement group_id="O6" value="-0.03" spread="0.27"/>
                    <measurement group_id="O7" value="0.16" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.2"/>
                    <measurement group_id="O2" value="-2.7" spread="2.1"/>
                    <measurement group_id="O3" value="-2.3" spread="3.0"/>
                    <measurement group_id="O4" value="-1.8" spread="1.5"/>
                    <measurement group_id="O5" value="-2.0" spread="1.9"/>
                    <measurement group_id="O6" value="-1.0" spread="2.6"/>
                    <measurement group_id="O7" value="1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.11"/>
                    <measurement group_id="O2" value="-0.62" spread="0.74"/>
                    <measurement group_id="O3" value="-0.68" spread="1.39"/>
                    <measurement group_id="O4" value="-0.13" spread="1.22"/>
                    <measurement group_id="O5" value="-0.14" spread="0.80"/>
                    <measurement group_id="O6" value="-0.55" spread="1.20"/>
                    <measurement group_id="O7" value="-0.48" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 2</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 2</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.075" spread="0.078"/>
                    <measurement group_id="O2" value="-0.110" spread="0.071"/>
                    <measurement group_id="O3" value="0.022" spread="0.120"/>
                    <measurement group_id="O4" value="-0.037" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.21"/>
                    <measurement group_id="O2" value="0.30" spread="0.14"/>
                    <measurement group_id="O3" value="-0.45" spread="0.49"/>
                    <measurement group_id="O4" value="-0.55" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.07"/>
                    <measurement group_id="O2" value="0.05" spread="0.07"/>
                    <measurement group_id="O3" value="-0.17" spread="0.27"/>
                    <measurement group_id="O4" value="-0.13" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.0" spread="1.4"/>
                    <measurement group_id="O3" value="0.7" spread="1.2"/>
                    <measurement group_id="O4" value="0.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.14"/>
                    <measurement group_id="O2" value="-1.00" spread="0.57"/>
                    <measurement group_id="O3" value="0.37" spread="1.15"/>
                    <measurement group_id="O4" value="-0.03" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea</title>
        <description>Blood samples were collected for analysis of hematology parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea</title>
          <description>Blood samples were collected for analysis of hematology parameters including Calcium, Glucose, Potassium, Sodium, Urea. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.086"/>
                    <measurement group_id="O2" value="0.040" spread="0.065"/>
                    <measurement group_id="O3" value="0.108" spread="0.027"/>
                    <measurement group_id="O4" value="0.050" spread="0.055"/>
                    <measurement group_id="O5" value="-0.045" spread="0.106"/>
                    <measurement group_id="O6" value="-0.035" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.142"/>
                    <measurement group_id="O2" value="0.124" spread="0.093"/>
                    <measurement group_id="O3" value="0.167" spread="0.044"/>
                    <measurement group_id="O4" value="0.073" spread="0.026"/>
                    <measurement group_id="O5" value="0.052" spread="0.098"/>
                    <measurement group_id="O6" value="-0.032" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.177"/>
                    <measurement group_id="O2" value="0.160" spread="0.067"/>
                    <measurement group_id="O3" value="0.157" spread="0.061"/>
                    <measurement group_id="O4" value="0.100" spread="0.059"/>
                    <measurement group_id="O5" value="-0.023" spread="0.080"/>
                    <measurement group_id="O6" value="-0.005" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.80"/>
                    <measurement group_id="O2" value="-0.78" spread="0.69"/>
                    <measurement group_id="O3" value="-0.05" spread="0.45"/>
                    <measurement group_id="O4" value="-0.17" spread="0.46"/>
                    <measurement group_id="O5" value="-0.47" spread="0.46"/>
                    <measurement group_id="O6" value="-0.33" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.81"/>
                    <measurement group_id="O2" value="-0.70" spread="0.62"/>
                    <measurement group_id="O3" value="-0.17" spread="0.52"/>
                    <measurement group_id="O4" value="-0.72" spread="0.35"/>
                    <measurement group_id="O5" value="-1.02" spread="0.55"/>
                    <measurement group_id="O6" value="-0.40" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.96"/>
                    <measurement group_id="O2" value="-0.03" spread="1.00"/>
                    <measurement group_id="O3" value="-0.30" spread="0.67"/>
                    <measurement group_id="O4" value="-0.08" spread="0.38"/>
                    <measurement group_id="O5" value="-0.08" spread="1.21"/>
                    <measurement group_id="O6" value="-0.12" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.64"/>
                    <measurement group_id="O2" value="-0.17" spread="0.39"/>
                    <measurement group_id="O3" value="0.38" spread="0.42"/>
                    <measurement group_id="O4" value="0.57" spread="0.21"/>
                    <measurement group_id="O5" value="0.15" spread="0.74"/>
                    <measurement group_id="O6" value="-0.05" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.33"/>
                    <measurement group_id="O2" value="-0.06" spread="0.54"/>
                    <measurement group_id="O3" value="0.47" spread="0.37"/>
                    <measurement group_id="O4" value="0.18" spread="0.15"/>
                    <measurement group_id="O5" value="-0.02" spread="0.31"/>
                    <measurement group_id="O6" value="0.07" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.41"/>
                    <measurement group_id="O2" value="0.03" spread="0.43"/>
                    <measurement group_id="O3" value="0.23" spread="0.23"/>
                    <measurement group_id="O4" value="-0.07" spread="0.41"/>
                    <measurement group_id="O5" value="-0.10" spread="0.32"/>
                    <measurement group_id="O6" value="0.00" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.7"/>
                    <measurement group_id="O2" value="-2.7" spread="2.0"/>
                    <measurement group_id="O3" value="-0.3" spread="1.6"/>
                    <measurement group_id="O4" value="-0.8" spread="2.6"/>
                    <measurement group_id="O5" value="-2.3" spread="3.0"/>
                    <measurement group_id="O6" value="-0.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.7"/>
                    <measurement group_id="O2" value="-2.0" spread="2.9"/>
                    <measurement group_id="O3" value="-0.5" spread="0.8"/>
                    <measurement group_id="O4" value="1.0" spread="2.7"/>
                    <measurement group_id="O5" value="1.8" spread="3.4"/>
                    <measurement group_id="O6" value="0.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.8"/>
                    <measurement group_id="O2" value="-2.3" spread="2.4"/>
                    <measurement group_id="O3" value="-0.5" spread="1.2"/>
                    <measurement group_id="O4" value="0.8" spread="2.2"/>
                    <measurement group_id="O5" value="0.7" spread="3.3"/>
                    <measurement group_id="O6" value="0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.88"/>
                    <measurement group_id="O2" value="-0.52" spread="0.75"/>
                    <measurement group_id="O3" value="-2.58" spread="2.10"/>
                    <measurement group_id="O4" value="-0.43" spread="0.42"/>
                    <measurement group_id="O5" value="-1.18" spread="1.28"/>
                    <measurement group_id="O6" value="-0.20" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.04"/>
                    <measurement group_id="O2" value="-0.88" spread="0.79"/>
                    <measurement group_id="O3" value="-2.82" spread="2.01"/>
                    <measurement group_id="O4" value="-1.17" spread="0.31"/>
                    <measurement group_id="O5" value="-1.40" spread="1.21"/>
                    <measurement group_id="O6" value="-1.25" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="1.04"/>
                    <measurement group_id="O2" value="0.50" spread="1.69"/>
                    <measurement group_id="O3" value="-0.27" spread="0.91"/>
                    <measurement group_id="O4" value="-0.40" spread="1.39"/>
                    <measurement group_id="O5" value="-1.10" spread="1.67"/>
                    <measurement group_id="O6" value="-0.03" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Albumin and Total Protein in Cohort 1 and 3</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin, and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Albumin and Total Protein in Cohort 1 and 3</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin, and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.5"/>
                    <measurement group_id="O2" value="-1.8" spread="4.8"/>
                    <measurement group_id="O3" value="-3.5" spread="4.3"/>
                    <measurement group_id="O4" value="-3.2" spread="3.1"/>
                    <measurement group_id="O5" value="-4.8" spread="3.8"/>
                    <measurement group_id="O6" value="-2.8" spread="2.2"/>
                    <measurement group_id="O7" value="-3.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="5.8"/>
                    <measurement group_id="O2" value="-2.5" spread="6.9"/>
                    <measurement group_id="O3" value="-5.0" spread="7.4"/>
                    <measurement group_id="O4" value="-3.3" spread="5.3"/>
                    <measurement group_id="O5" value="-6.2" spread="7.1"/>
                    <measurement group_id="O6" value="-2.0" spread="3.6"/>
                    <measurement group_id="O7" value="-2.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Albumin and Total Protein in Cohort 2</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Albumin and Total Protein in Cohort 2</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period 1 (or the first available Dosing Period if Dosing Period 1 is unavailable). Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.0"/>
                    <measurement group_id="O2" value="-2.0" spread="0.0"/>
                    <measurement group_id="O3" value="-1.2" spread="2.7"/>
                    <measurement group_id="O4" value="-1.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="0.7"/>
                    <measurement group_id="O2" value="-4.5" spread="2.1"/>
                    <measurement group_id="O3" value="-1.5" spread="5.1"/>
                    <measurement group_id="O4" value="-3.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Albumin, Total Protein</title>
        <description>Blood samples were collected for analysis of hematology parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Albumin, Total Protein</title>
          <description>Blood samples were collected for analysis of hematology parameters including albumin and total protein. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.9"/>
                    <measurement group_id="O2" value="-2.3" spread="1.4"/>
                    <measurement group_id="O3" value="-2.2" spread="0.8"/>
                    <measurement group_id="O4" value="-3.3" spread="1.9"/>
                    <measurement group_id="O5" value="-3.7" spread="1.4"/>
                    <measurement group_id="O6" value="-0.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.6"/>
                    <measurement group_id="O2" value="-0.4" spread="2.2"/>
                    <measurement group_id="O3" value="0.2" spread="1.5"/>
                    <measurement group_id="O4" value="-2.5" spread="2.3"/>
                    <measurement group_id="O5" value="-0.7" spread="1.2"/>
                    <measurement group_id="O6" value="-1.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Follow-up (Day 25);n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.5"/>
                    <measurement group_id="O2" value="-0.3" spread="3.3"/>
                    <measurement group_id="O3" value="1.2" spread="1.0"/>
                    <measurement group_id="O4" value="0.2" spread="3.6"/>
                    <measurement group_id="O5" value="-1.7" spread="1.4"/>
                    <measurement group_id="O6" value="-0.5" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Day 7; n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="3.2"/>
                    <measurement group_id="O2" value="-2.5" spread="2.1"/>
                    <measurement group_id="O3" value="-4.0" spread="2.3"/>
                    <measurement group_id="O4" value="-1.8" spread="2.1"/>
                    <measurement group_id="O5" value="-4.5" spread="2.3"/>
                    <measurement group_id="O6" value="-1.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Day 15; n=10,5,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.7"/>
                    <measurement group_id="O2" value="0.2" spread="4.1"/>
                    <measurement group_id="O3" value="-0.3" spread="3.1"/>
                    <measurement group_id="O4" value="-1.3" spread="3.0"/>
                    <measurement group_id="O5" value="-1.0" spread="2.8"/>
                    <measurement group_id="O6" value="0.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein;Follow-up (Day 25); n=10,6,6,6,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="4.8"/>
                    <measurement group_id="O2" value="0.8" spread="4.9"/>
                    <measurement group_id="O3" value="0.5" spread="1.9"/>
                    <measurement group_id="O4" value="2.0" spread="4.4"/>
                    <measurement group_id="O5" value="-2.2" spread="2.5"/>
                    <measurement group_id="O6" value="-1.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 1 and Cohort 3</title>
        <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
        <time_frame>Baseline (Day-1) and Day 3</time_frame>
        <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1 and 3: Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 in one of the Periods of Cohort 1 and Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A:Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Part A:Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 1 and Cohort 3</title>
          <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
          <population>Safety population. In Cohort 1 and 3, participants were dosed in similar single ascending doses, cross-over sequences. Hence, combined totals for placebo arm is presented as pre-specified in protocol and reporting and analysis plan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 2</title>
        <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
        <time_frame>Baseline (Day -1) and Day 3</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: Fasted Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: Fed Placebo</title>
            <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 2</title>
          <description>Urine samples were collected from participants for analysis of specific gravity of urine. Urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, potential of hydrogen (pH), protein, specific gravity and Urobilinogen were analyzed by dipstick method. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug in Dosing Period
1 (or the first available Dosing Period if Dosing Period 1 is unavailable).</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Abnormal Findings for Urine Parameters</title>
        <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
        <time_frame>Baseline (Day -2), Day 7, Day 15 and Follow-up (Day 25)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo BID</title>
            <description>Participants received repeat doses of placebo BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Abnormal Findings for Urine Parameters</title>
          <description>Blood samples were collected for analysis of hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes. Baseline is defined as the last available, non-missing assessment prior to the first administration of study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen; Follow-up (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Non-zero Concentration (AUC [0-t]) Following Single Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods. The PK Parameter population comprised of all randomized participants who received at least one dose of active treatment and who had GSK3352589 Pharmacokinetic parameter estimates from any portion of the study.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population comprised of all randomized participants who received at least one dose of active treatment and who had GSK3352589 Pharmacokinetic parameter estimates from any portion of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Non-zero Concentration (AUC [0-t]) Following Single Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods. The PK Parameter population comprised of all randomized participants who received at least one dose of active treatment and who had GSK3352589 Pharmacokinetic parameter estimates from any portion of the study.</description>
          <population>Pharmacokinetic Parameter Population comprised of all randomized participants who received at least one dose of active treatment and who had GSK3352589 Pharmacokinetic parameter estimates from any portion of the study.</population>
          <units>Hour*Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8452" spread="75.5"/>
                    <measurement group_id="O2" value="1.306" spread="66.2"/>
                    <measurement group_id="O3" value="2.480" spread="49.4"/>
                    <measurement group_id="O4" value="4.630" spread="63.9"/>
                    <measurement group_id="O5" value="2.771" spread="38.9"/>
                    <measurement group_id="O6" value="2.030" spread="24.4"/>
                    <measurement group_id="O7" value="9.416" spread="119.1"/>
                    <measurement group_id="O8" value="11.67" spread="124.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Single Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Single Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hour*Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9652" spread="83.7"/>
                    <measurement group_id="O2" value="1.446" spread="73.0"/>
                    <measurement group_id="O3" value="2.738" spread="46.3"/>
                    <measurement group_id="O4" value="5.031" spread="63.6"/>
                    <measurement group_id="O5" value="3.648" spread="53.3"/>
                    <measurement group_id="O6" value="2.372" spread="27.8"/>
                    <measurement group_id="O7" value="10.75" spread="119.1"/>
                    <measurement group_id="O8" value="17.49" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2339" spread="74.1"/>
                    <measurement group_id="O2" value="0.2919" spread="58.6"/>
                    <measurement group_id="O3" value="0.5541" spread="40.0"/>
                    <measurement group_id="O4" value="0.7318" spread="65.3"/>
                    <measurement group_id="O5" value="0.5397" spread="38.6"/>
                    <measurement group_id="O6" value="0.4317" spread="15.2"/>
                    <measurement group_id="O7" value="1.325" spread="111.6"/>
                    <measurement group_id="O8" value="1.157" spread="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Time to Reach Cmax (Tmax) Following Single Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Time to Reach Cmax (Tmax) Following Single Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.50" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="1.25" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O6" value="0.750" lower_limit="0.50" upper_limit="2.0"/>
                    <measurement group_id="O7" value="1.25" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.50" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Terminal Elimination Half-life (t1/2) Following Single Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including t1/2 following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 1: GSK3352589 2 mg</title>
            <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 1: GSK3352589 5 mg</title>
            <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Cohort 1: GSK3352589 15 mg</title>
            <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Cohort 1: GSK3352589 50 mg</title>
            <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: GSK3352589 150 mg</title>
            <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: GSK3352589 400 mg</title>
            <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Terminal Elimination Half-life (t1/2) Following Single Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including t1/2 following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="83.1"/>
                    <measurement group_id="O2" value="7.83" spread="65.1"/>
                    <measurement group_id="O3" value="17.1" spread="32.4"/>
                    <measurement group_id="O4" value="17.0" spread="11.8"/>
                    <measurement group_id="O5" value="19.2" spread="33.7"/>
                    <measurement group_id="O6" value="20.5" spread="19.7"/>
                    <measurement group_id="O7" value="16.1" spread="58.9"/>
                    <measurement group_id="O8" value="14.4" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Cmax Following Single Dose Administration of GSK3352589-Food Effect</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Cmax Following Single Dose Administration of GSK3352589-Food Effect</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5397" spread="38.6"/>
                    <measurement group_id="O2" value="0.4317" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.8000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5940</ci_lower_limit>
            <ci_upper_limit>1.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC (0-t) Following Single Dose Administration of GSK3352589- Food Effect</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC (0-t) Following Single Dose Administration of GSK3352589- Food Effect</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population</population>
          <units>Hours*Nanogram per milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.019" spread="0.1287"/>
                    <measurement group_id="O2" value="0.7081" spread="0.1287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.7325</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5267</ci_lower_limit>
            <ci_upper_limit>1.019</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC (0-infinity) Following Single Dose Administration of GSK3352589- Food Effect</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36, 48 Hours Post-dose</time_frame>
        <population>Pharmacokinetic Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
            <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC (0-infinity) Following Single Dose Administration of GSK3352589- Food Effect</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-infinity) following administration of GSK3352589 in fasted and fed condition to assess the effect of food on pharmacokinetics of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part A was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population</population>
          <units>Hours*Nanogram per milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.294" spread="0.2105"/>
                    <measurement group_id="O2" value="0.8636" spread="0.1630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.6502</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3876</ci_lower_limit>
            <ci_upper_limit>1.091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: AUC (0-t) Following Repeat Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: AUC (0-t) Following Repeat Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-t) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Hour*Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n=6, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4479" spread="89.6"/>
                    <measurement group_id="O2" value="0.4647" spread="75.1"/>
                    <measurement group_id="O3" value="2.167" spread="41.2"/>
                    <measurement group_id="O4" value="3.459" spread="84.6"/>
                    <measurement group_id="O5" value="2.934" spread="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n=5, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7147" spread="84.9"/>
                    <measurement group_id="O2" value="0.7176" spread="53.4"/>
                    <measurement group_id="O3" value="3.763" spread="21.5"/>
                    <measurement group_id="O4" value="6.121" spread="35.0"/>
                    <measurement group_id="O5" value="8.061" spread="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC [0-24]) Following Repeat Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-24) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC [0-24]) Following Repeat Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-24) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Hour*Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n=6, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.389" spread="58.6"/>
                    <measurement group_id="O2" value="1.641" spread="51.5"/>
                    <measurement group_id="O3" value="7.285" spread="40.6"/>
                    <measurement group_id="O4" value="11.41" spread="65.5"/>
                    <measurement group_id="O5" value="12.31" spread="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n=5, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.988" spread="62.5"/>
                    <measurement group_id="O2" value="1.970" spread="44.1"/>
                    <measurement group_id="O3" value="9.383" spread="23.2"/>
                    <measurement group_id="O4" value="15.73" spread="33.8"/>
                    <measurement group_id="O5" value="24.11" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-tau) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-tau) following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Hour*Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n=6, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5028" spread="87.9"/>
                    <measurement group_id="O2" value="0.5468" spread="72.9"/>
                    <measurement group_id="O3" value="2.522" spread="43.4"/>
                    <measurement group_id="O4" value="4.055" spread="80.0"/>
                    <measurement group_id="O5" value="3.673" spread="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n=5, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8303" spread="82.7"/>
                    <measurement group_id="O2" value="0.8417" spread="53.8"/>
                    <measurement group_id="O3" value="4.421" spread="22.1"/>
                    <measurement group_id="O4" value="7.242" spread="34.9"/>
                    <measurement group_id="O5" value="9.914" spread="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Cmax Following Repeat Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Cmax Following Repeat Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including Cmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n=6, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1308" spread="93.0"/>
                    <measurement group_id="O2" value="0.1394" spread="51.2"/>
                    <measurement group_id="O3" value="0.5255" spread="17.9"/>
                    <measurement group_id="O4" value="0.8191" spread="78.5"/>
                    <measurement group_id="O5" value="0.6607" spread="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n=5, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1655" spread="74.3"/>
                    <measurement group_id="O2" value="0.1919" spread="31.3"/>
                    <measurement group_id="O3" value="0.7149" spread="26.4"/>
                    <measurement group_id="O4" value="1.260" spread="36.7"/>
                    <measurement group_id="O5" value="1.526" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Tmax Following Repeat Dose Administration of GSK3352589</title>
        <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 1; Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 10, 11, 12, 14, 16, 24 Hours Post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK3352589 5 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 5 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK3352589 15 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 15 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK3352589 50 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 50 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK3352589 100 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK3352589 200 mg BID</title>
            <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Tmax Following Repeat Dose Administration of GSK3352589</title>
          <description>Blood samples were collected from participants for pharmacokinetic analysis including Tmax following administration of GSK3352589. Pharmacokinetic analysis of GSK3352589 in Part B was conducted by non-compartmental methods.</description>
          <population>Pharmacokinetic Parameter Population. Only those participants with data available at specified time point were analyzed (reported by n=X in category titles).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n=6, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.767" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O5" value="0.750" lower_limit="0.50" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; n=5, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.500" lower_limit="0.50" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.50" lower_limit="0.50" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0.50" upper_limit="2.5"/>
                    <measurement group_id="O5" value="0.500" lower_limit="0.50" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-SAEs were collected up to 64 days in Cohort 1, up to 30 days in Cohort 2, up to 30 days in Cohort 3 each in Part A of the study and up to 25 days in Part B of the study.</time_frame>
      <desc>SAEs and non-SAEs were collected using Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Cohort 1: Placebo</title>
          <description>Participants received placebo tablet matching GSK3352589 orally in each Period of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E2">
          <title>Part A: Cohort 1: GSK3352589 2 mg</title>
          <description>Participants received GSK3352589 2 mg tablet orally in Period 1 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E3">
          <title>Part A: Cohort 1: GSK3352589 5 mg</title>
          <description>Participants received GSK3352589 5 mg tablet orally in Period 2 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E4">
          <title>Part A: Cohort 1: GSK3352589 15 mg</title>
          <description>Participants received GSK3352589 15 mg tablet orally in Period 3 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E5">
          <title>Part A: Cohort 1: GSK3352589 50 mg</title>
          <description>Participants received GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E6">
          <title>Part A: Cohort 2: Fasted Placebo</title>
          <description>Participants received placebo tablet matching GSK3352589 without food in Period 1 of Cohort 2 in Part A of the study.</description>
        </group>
        <group group_id="E7">
          <title>Part A: Cohort 2: Fed Placebo</title>
          <description>Participants received placebo tablet matching GSK3352589 with food in Period 2 of Cohort 2 in Part A of the study.</description>
        </group>
        <group group_id="E8">
          <title>Part A: Cohort 2: GSK3352589 Fed 25 mg</title>
          <description>Participants received GSK3352589 25 mg tablet with food in Period 2 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E9">
          <title>Part A: Cohort 2: GSK3352589 Fasted 25 mg</title>
          <description>Participants received GSK3352589 25 mg tablet without food in Period 1 of Cohort 1 in Part A of the study.</description>
        </group>
        <group group_id="E10">
          <title>Part A: Cohort 3: Placebo</title>
          <description>Participants received placebo tablet matching GSK3352589 in each Period of Cohort 3 in Part A of the study.</description>
        </group>
        <group group_id="E11">
          <title>Part A: Cohort 3: GSK3352589 150 mg</title>
          <description>Participants received GSK3352589 150 mg tablet in Period 1 of Cohort 3 in Part A of the study.</description>
        </group>
        <group group_id="E12">
          <title>Part A: Cohort 3: GSK3352589 400 mg</title>
          <description>Participants received GSK3352589 400 mg tablet in Period 2 of Cohort 3 in Part A of the study.</description>
        </group>
        <group group_id="E13">
          <title>Part B: Placebo BID</title>
          <description>Participants received repeat oral doses of placebo BID (twice a day) tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="E14">
          <title>Part B: GSK3352589 5 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 5 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="E15">
          <title>Part B: GSK3352589 15 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 15 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="E16">
          <title>Part B: GSK3352589 50 mg BID</title>
          <description>Participants received repeat oral doses of GSK3352589 50 mg BID tablet administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="E17">
          <title>Part B: GSK3352589 100 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 100 mg BID administered for 14 days in Part B of the study.</description>
        </group>
        <group group_id="E18">
          <title>Part B: GSK3352589 200 mg BID</title>
          <description>Participants received repeat doses of GSK3352589 200 mg BID administered for 14 days in Part B of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

